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In the field of precision medicine, researchers adopt machine learning techniques to solve health-
related problems, while applying such methods needs substantial health data. Electronic health
records (EHRs) and mobile sensor data have become two important and abundant sources of health
data. However, the modeling techniques for applying such data are still under development. The
objective of this dissertation is to develop innovative frameworks of machine learning methods to
use EHRs and/or mobile sensor data for disease prediction and precision medicine.
The first problem we address is using retrospectively collected EHRs data to learn latent patterns
that can inform patient’s health status. To handle data challenges in EHRs, we propose an approach
that is based on multivariate generalized linear models in which latent Gaussian processes are
introduced to model between-marker correlations over time. Using the inferred latent processes,
we integrate irregularly measured health markers of mixed types into composite scores and apply
hierarchical clustering to learn latent subgroup structures among patients. We demonstrate the
utility of the proposed model through simulation studies and an EHRs dataset for type 2 diabetes
(T2D) patients.
The next topic we investigate is recommending optimal individualized treatments to patients in
EHRs data. To handle the multicategory comparison of treatments and confounding effects among
patients, we incorporate the latent subgroups and use the one-versus-one approach to extend a
matched learning model. Each matched learning for binary treatments is implemented by a weighted
support vector machine with matched pairs of patients. Using the proposed method, we select the
optimal treatments from four classes of T2D treatments and achieve a better control of glycated
hemoglobin than one-size-fits-all rules for an EHRs dataset.
The last problem we explore is using mobile sensor data to predict outcomes and identify
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objective biomarkers related to adverse posttraumatic neuropsychiatric sequelae. To overcome
the difficulties in utilizing mobile sensor data, we develop a two-stage model that considers the
measurement resolution and temporal pattern of features collected from mobile sensors. Finally, we
apply our method to predict the pain experience of participants who experienced traumatic events,
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CHAPTER 1: INTRODUCTION
In the modern era of healthcare, precision medicine has attracted great attentions from researchers
in fields of statistical and biomedical science. Precision medicine is a medical paradigm that evolves
individual characteristics of each patient such as demographics, lab test results, and genetic
information, to optimize treatments (Ginsburg and Phillips, 2018).
As the emergence of large-scaled electronic systems, one important source of patient’s health
data is the electronic health record (EHR) which automatically captures patients health information
through normal medical practice (Gunter and Terry, 2005; Cebul et al., 2011; Herrin et al., 2012).
EHRs store patient health information in a digit format and the data can be shared across different
institutions, so doctors and researchers have more opportunities to utilize the vast amounts of
longitudinal data recorded in every moment. In general, EHRs record the information including
patient demographics, vital signs, laboratory test results, medications, disease diagnosis codes, and
medical insurances, on a large population over long time frames. Compared to experimental research
like the randomized clinical trial (RCT), such observational studies provide stronger real world
evidences because of larger patient populations, more flexible patient eligibility criteria, and longer
duration for observations. Furthermore, studies using large-scaled EHRs may reflect real-world
patterns of treatment pathway which can not be conducted and observed in RCTs (Hripcsak et al.,
2016). Therefore, integrative analyses of these information across time provide great opportunities to
understand individual patient’s disease progression and susceptibility in real world settings, so as to
predict disease prognosis and optimize personalized treatments adapted to evolving patient-specific
features.
Although EHR data have advantages to the research in precision medicine, there are still some
major challenges in applying such data. First of all, health markers in EHRs are often correlated and
irregularly measured. Data sparsity and missing data can also be serious issues. In addition, EHR
data have a mixture of health marker types such as continuous, binary, and count data. Moreover,
there are underlying homogeneities and heterogeneities among thousands of patients in the data
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source. Thus, existing approaches for longitudinal data have limitations and cannot handle all the
data challenges.
In Chapter 2, we propose an innovative framework to take advantage of the rich health information
in retrospectively collected EHRs and identify latent patient subgroups. The framework is built on
multivariate generalized linear models (GLMs) which jointly analyze correlated and mixed type of
health markers over time. In multivariate GLMs, covariate effects are time dependent and latent
Gaussian processes are introduced to characterize between-marker correlations over time. Using
inferred latent processes, we integrate the irregularly measured health markers of mixed types
into composite scores and apply hierarchical clustering to learn latent subgroup structures among
patients. We use the method of moments and kernel-weighted local estimating equations to estimate
parameters that represent the covariate effects and between-marker correlations. Also, we adopt
an inverse weighted method to standardize the intensity of health marker measurements. In this
way, the bias, which is caused by heterogeneous temporal patterns of different health markers,
in parameter estimation is reduced. We prove theoretical properties of the proposed estimators
such as Fisher consistencies and asymptotic distributions. To demonstrate the performance of the
proposed framework on finite samples, we apply our method to type 2 diabetes (T2D) patients
in an EHR dataset collected from the Ohio State University Wexner Medical Center Information
Warehouse (OSU-WMCIW). The analysis shows different trends of age, sex, and race effects on
hypertension/high blood pressure (HBP), total cholesterol (TC), glycated hemoglobin (HbA1c),
high-density lipoprotein (HDL), and medications. The associations among these markers vary over
time during the study window. The hierarchical clustering of patients reveals four subgroups, and
each patient subgroup is summarized by a unique profile based on patient’s health status. The
latent patterns are further confirmed by another split of the EHRs for the same cohort, suggesting
that an effective healthcare management for these patients should be performed separately for each
subgroup.
In pace with the rapid development of computational power, an increasing number of recent
literature have adopted machine learning techniques to precision medicine (Mesko, 2017). Broadly
speaking, these machine learning research estimate the individualized treatment rule (ITR) through
maximizing some clinical outcomes. Most of the existing methods are designed for the comparison
between binary treatments and/or for RCTs. Nevertheless, in real world data such as the EHR
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dataset we handle with, there are multicategory treatments (86 types of T2D drugs) and large
samples of patients (over 50,000 patients) with diverse backgrounds.
To fill up the gap between existing methods and real world evidence, in Chapter 3, we extend a
matched learning method (Wu et al., 2020) to recommend the most effective treatment for each
individual in the EHR dataset. We handle multicategory treatments by the one-versus-one approach
and majority voting strategy (Bishop, 2006). Each matched learning classifier for two treatments
is implemented by a weighted support vector machine (SVM) (Cortes and Vapnik, 1995) with
matched sets of patients. The matched set of a target patient is defined as a group of patients
who have the same group membership and have similar characteristics as him/her, but they receive
an alternative treatment. By comparing a target patient only with patients in his/her matched
set, the confounding effects are reduced, so, in this case, the difference in the clinical outcome
reflects the treatment effect. If the average clinical outcome over the matched set is more beneficial,
then the target patient should switch from the assigned treatment to the alternative treatment.
Otherwise, the assigned treatment is already the optimal treatment for the target patient. Lastly,
the treatment with the highest vote across all binary comparisons is set to be the optimal treatment
of all classes. In a real data application, we estimate the optimal individualized treatment among
four types of T2D treatments for over five thousands patients (a different cohort from Chapter 2) in
the EHR dataset of the OSU-WMCIW. We compare our method with four one-size-fits-all rules
and two treatment rules estimated by Q-learning (Watkins and Dayan, 1992; Murphy, 2005; Qian
and Murphy, 2011), and the comparison shows the proposed method has a better management of
HbA1c level than other models by at least 5%-13%.
Besides EHRs, personal sensing data collected from mobile sensor also have received increasing
interests from various areas, especially in health care. Mobile sensors embedded in smartphones
(short messaging service, microphone, global positioning systems (GPS)), and smartwatches (electro-
cardiogram (ECG), accelerometer, time stamp) continuously monitor the health-related indices and
activities of subjects. Thus, doctors and patients can precisely understand the treatment response,
disease progression, and health status through the continuous measurement of health markers.
However, modeling techniques for mobile sensor data are still under development. The challenges
of handling mobile sensor data come from three major aspects. First of all, mobile sensor data
are high dimensional. Secondly, mobile sensor data are often correlated and have lagged effects on
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outcome variables. Lastly, data collected from different sensors can have different time scales. For
example, heart rate data have thousands of measurements for each day and the data have cyclic
patterns for the sample person. In the meantime, actigraphy data just have daily measurements.
Most of the existing literature simply treat all the features as independent predictors and fit them
using complicated machine learning or deep learning models, but these data challenges will bring in
biases to the prediction indeed.
In Chapter 4, we create a two-stage semi-parametric method for modeling clinical outcomes and
identifying objective biomarkers related to psychiatric disorder using mobile sensor data. The first
stage adopts a linear regression model to describe the relationship between different domains/sensors
of features and health markers. The model handles the effect of time scales and retrospective
measurements on the features by assigning weights to features measured at different time points.
We apply the least absolute shrinkage and selection operator (LASSO) method (Tibshirani, 1996;
Tibshirani et al., 2004) to select the most informative features and improve the model interpretability.
In the second stage, we implement the selected features and estimated weights to a support vector
regression (SVR) model (Drucker et al., 1997) to improve the prediction accuracy. This step accounts
for non-linear interactions and between-domain comorbidities of features that are not captured
in the first stage. We verify the proposed method on a sample of participants in the Advancing
Understanding of RecOvery afteR traumA (AURORA) study (McLean et al., 2020). For participants
who experienced traumatic events, this application studies the relationship between construct scores,
which quantify the pain experience of participants, and two domains of mobile sensor features
at six follow-up time points after the events. The two domains of mobile sensor features include
eight activity features and eleven heart rate variability (HRV) features collected from smartwatches.
Compared to a SVR model that does not adjust for feature selection, measurement resolutions, and
temporal patterns, the proposed method achieves a better prediction performance by using only
12% of the total features.
Each of Chapters 2 to 4 defines the research problem, introduces the background and existing
literature, explains the proposed method, demonstrates the method through numeric examples,
and summarizes the contributions and conclusions. Chapter 5 discusses the limitations of this
dissertation and provides potential directions for future research.
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CHAPTER 2: LEARNING LATENT HETEROGENEITY FOR TYPE 2
DIABETES PATIENTS USING LONGITUDINAL HEALTH MARKERS IN
ELECTRONIC HEALTH RECORDS
2.1 Introduction
In the modern era of precision medicine, one important source of patient’s health data is EHRs.
EHRs data consist of longitudinal medical records from a large number of patients in one or
more electronic healthcare systems that digitally capture measurements of patients health status
through normal medical practices (Gunter and Terry, 2005; Cebul et al., 2011; Herrin et al., 2012),
including patient’s vital signs, laboratory measurements, disease diagnosis codes, procedure codes,
and medications. Benefits of EHRs include cost effectiveness, real time updates, and reflections on
patients disease course and healthcare managements in realistic settings. Therefore, integrative
analyses of this information over time provide great opportunities to understand the heterogeneity of
patient’s disease progression and susceptibility in real world settings, which is useful for monitoring
disease prognosis and optimizing personalized healthcare management.
Due to the retrospective nature of EHRs, the analysis of EHRs is complicated by the following
challenges: first, the health markers measured over time are multivariate and the measurements can
be either continuous (e.g., lab measures), binary (e.g., disease diagnoses), or counts (e.g., number of
medications); second, for each patient, the health marker data are collected at each clinical encounter
so the measurement times can be irregular, sparse, and heterogeneous across patients; third, the
measurement times are often informative to patients health status or health care processes.
This work is motivated by the analyses of EHRs of T2D patients obtained from the OSU-
WMCIW. The data collection spanned a time period of 8 years (between 2011 and 2018) from
a total of 58,490 patients. The data contained patients medical records of glycated hemoglobin,
high-density lipoprotein, total cholesterol, hypertension, and all medications prescribed at each
clinical encounter. Because these markers were of different types and were not measured at the
same time across and within patients, directly combining the values from these markers is neither
meaningful nor feasible. For example, Figure 2.1 gives a snapshot of the measurement time of
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several health markers from 20 randomly selected patients. Clearly, each marker was measured
sparsely at irregular times for each patient, and the measurement time patterns vary significantly



































Figure 2.1: Observation time patterns of 5 health markers for 20 randomly selected T2D patients in
the EHRs at the OSU-WMCIW.
Joint models based on linear or generalized mixed effects models have been commonly used
for analyzing multivariate longitudinal data (Verbeke et al., 2014). In the joint models, various
distribution families are used (Verbeke and Molenberghs, 2000; Davidian and Giltinan, 2003;
Molenberghs and Verbeke, 2005), and subject-specific random effects are shared across all health
markers to explain their dependence due to a finite number of latent variables. For example,
Lambert and Vandenhende (2002) jointly analyzed three repeatedly measured longitudinal outcomes
using copula models in a dose titration safety study; Gueorguieva and Sanacora (2006) proposed
correlated probit models for joint analysis of repeated measurements with ordinal and continuous
health markers. Some extensions allowed time-dependent effects (Huang et al., 2002; Fan and Zhang,
2008), but assumed constant between-marker dependence over time. However, assuming parametric
patterns or attributing the dependence to a few time-invariant random effects is rather restrictive
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especially for modeling EHRs over a long period of time, since in EHRs, the trajectories of the
health markers and their dependence may vary over time depending on the disease progression and
medication usage for each patient. Moreover, it is computationally challenging to maximize a joint
likelihood in the presence of a large number of patients and many health markers.
Machine learning approaches have been also proposed to perform EHR analysis, such as deep
Poisson factor models (Henao et al., 2016), tensor factorization and non-negative matrix factorization
(Ho et al., 2014), and deep exponential families (Miscouridou et al., 2018). These approaches,
although more flexible than aforementioned statistical models, are less interpretable and are highly
computationally intensive, requiring substantial work for data engineering and model tuning. More
importantly, none of these approaches can account for irregular but informative measurement
patterns as seen in EHRs.
In this chapter, we seek to strike a balance between the complex statistical modelling and flexible
machine learning methods, while accounting for the unique challenges in EHRs. To conduct an
integrative analysis of EHRs, we extend the multivariate GLMs by assuming appropriate distribution
and link functions depending on the marker type. We allow the effects of covariates on health
markers to be time-varying. Moreover, to account for the time-varying dependence among health
markers, we introduce latent Gaussian processes into the models, where the covariance matrix is
assumed to vary over time. For estimation, we adopt kernel smoothing method to pool information
across time points and patients and apply weights to account for the heterogeneous patterns of
measurement times. The inferred latent processes represent patients underlying health status, so in
order to integrate these mixed-type health markers, we use the inferred latent processes to calculate
the distances between any two patients using the Mahalanobis distance (De Maesschalck et al.,
2000). Finally, we apply hierarchical clustering to identify patients health patterns and characterize
between-group heterogeneities.
The remaining parts of this chapter are organized as follows. In Section 2.2, we propose our
models and describe main ideas. We then provide inferences on estimating model parameters
and procedures to perform numerical computations. In Section 2.3, we derive the asymptotic
distributions of the estimators. We conduct simulation studies in Section 2.4. In Section 2.5, we




2.2.1 Statistical Models for Integrative Analysis
Suppose EHR data are obtained from n patients. For the ith patient, let Xi be m-dimensional
baseline covariates. Among p health markers, let Yik(t) denote the measurement of the kth health
marker at time t. We suppose Yik(t) is measured at time points tik1, tik2, . . . , tiknik , where nik is
the total count of observations on the kth health marker for the ith patient. The total number of
observations up to time t can be represented by a counting process Nik(t) ≡
∑nik
j=1 I(tikj ≤ t), where
I(·) is the indicator function. Since the documentation times are patient’s clinical encounters in the
EHR system, patterns of these documentation/measurement time points may carry information on
patients health status. Thus, we model the intensity of Nik(t) as





where λk(t) is a baseline intensity function, and γk is a vector of intensity parameters. By modeling
the intensity of EHR measurement rates, one can adjust for the bias of informative measurement
patterns and account for between patient heterogeneity.
We further assume Yik(t) follows a distribution in an exponential family model as follows:




+ ck (y, φik(t))
}
, (2.2)
where θik(t) and φik(t) are the canonical parameter and the dispersion parameter, respectively,
specific to each patient and each health marker. ak(·), bk(·), and ck(·) are known functions. Let
θik(t) = gk(µik(t)), where gk(·) is the canonical link function, and µik(t) is the mean of Yik(t). To
capture the patient heterogeneity and dependence, we assume, at time t,
gk(µik(t)) = XTi βk(t) + εik(t),
εi(t) ∼ Np (0,Ω(t)) , (2.3)
where βk(t) is a vector of regression coefficients for covariates Xi. εik(t) is the kth element of the
latent Gaussian process εi(t) = {εi1(t), εi2(t), . . . , εip(t)}T . εi(t) is independent of Xi, and it follows
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a mean-zero multivariate Gaussian distribution with a covariance matrix Ω(t). Estimating variances
locally will requires dense measurements from the same health marker, which is not the case for the
EHRs. Moreover, in our empirical application the estimated variances do not vary much across time
(Section 2.6). Thus, to ensure numerical stability in subsequent analysis, we assume each latent
process to have a constant variance and the constant is estimated using historical records. Hence,
in Ω(t), only the correlations among health markers, that is, the off-diagonal elements need to be
estimated.
Under the proposed models (2.2) and (2.3), each measurement Yik(t) can be uniquely represented
by the latent process εik(t). Since εik(t) has the same scale for different k, one can integrate the
latent processes {εik(t) : k = 1, 2, . . . , p} as an alternative way to integrate the mixed-type health




[εi(t)− εj(t)]T Ω−1(t) [εi(t)− εj(t)] dt
}1/2
. (2.4)
Thus, there are several important advantages of using the proposed models to perform an integrative
analysis of mixed-type health markers. First of all, despite the health markers are irregularly
measured and mixed-type, we can map them onto the same scale to align patients and characterize
the between-patients heterogeneity. In addition, the dimension of latent processes can be further
reduced to some lower dimensional subspaces than the number of health markers. Therefore, through
the representation of latent processes, we achieve a dimension reduction.
2.2.2 Model Parameter Estimation
First, we use marker-specific Anderson-Gill intensity models (Andersen and Gill, 1982) to
estimate γk in (2.1). With the estimator γ̂k, we normalize the counting process Nik(t) by letting




. Thus, the normalized counting process is homogeneous across
different patients and different health markers.








Xi [Yik(s)− E [Yik(t)|Xi]]Kh1n(s− t)dÑik(s) = 0, (2.5)
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where Kh(z) = h−1K(z/h) with K(z) being a symmetric kernel function, and h1n is the bandwidth
of Kh(z). Essentially, we assign weights to the observed measurements Yik(s) near t, and we pool
them together across all patients to estimate the mean (first moment) of Yik(t). This pooling process
relies on the kernel smoothing. Also, pooling information across observations nearby and across
patients overcomes the difficulty in parameter estimations that some sparsely measured health
markers do not have sufficient samples at some time points. Moreover, using dÑik(s) instead of
dNik(s), we remove the heterogeneity of informative measurement time points among patients in a
similar spirit as inverse probability weighting.
Similarly, to estimate the correlation between two latent processes, σkl(t) = Cov(εik(t), εil(t)),









K̃h2n(s− t, s′ − t)dÑik(s)dÑil(s′) = 0,
(2.6)
where K̃h(z1, z2) is a bivariate kernel function with bandwidth h2n.
2.2.3 Numerical Computation
When the link functions in (2.3) take some simple forms, E [Yik(t)|Xi] in (2.5) and E [Yik(t)Yil(t)|Xi]
in (2.6) can be explicitly computed. Specifically, for gk(z) = gl(z) = z,
E [Yik(t)|Xi] = XTi βk(t),
and
E[Yik(t)Yil(t)|Xi] = XTi βk(t)XTi βl(t) + σkl(t).
When gk(z) takes a general form, we can compute the above expectations using the Gauss-Hermite
quadrature method (Abramowitz and Stegun, 1965).
Since Un,k(βk(t)) is only related to the parameter βk(t), we can solve (2.5) and obtain β̂k(t)
for each health marker k, separately. Similarly, plugging β̂k(t) and β̂l(t) to (2.6), we can solve the
equation and obtain σ̂kl(t) for each pair of health markers, separately. Therefore, even with many
health markers, that is, p is moderate or large, our algorithm can efficiently handle the computation
burden by solving the estimating equations separately. Finally, we apply the above procedures for
time grids t1, t2, . . . , tN to obtain the parameter estimators over the whole range of the follow-up.
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A distance matrix D can be obtained by computing the Mahalanobis distance in (2.4) between














∣∣∣Yi(t), β̂k(t), σ̂kl(t)] , (2.8)













∣∣∣εi(t), β̂k(t), σ̂kl(t))P (εi(t)|σ̂kl(t)) dεi(t) .
The subsequent steps can be calculated using the Gauss-Hermite quadrature method as well, and
the details are given in Appendix A.1.
2.2.4 Data-adaptive Selection of Bandwidths
Our asymptotic results in Appendix A suggest the bandwidths h1n and h2n can be chosen,
respectively, on the order of n−1/3 and n−1/4. However, for practical applications, we consider a
data-adaptive method for selecting the bandwidths (Cao et al., 2015). The key idea is using observed
data to obtain the empirical bias and variability of the estimators in terms of the bandwidths.
Consequently, we search for the bandwidths that minimize the empirical mean squared error of
selecting them.
Specifically, to choose the optimal bandwidth h1n for estimating β̂k(t), we first consider a
reasonable range of bandwidths. For a fixed bandwidth h and a fixed time point t, we denote
β̂kh(t) to the estimator for βk(t). To estimate the bias of β̂kh(t), we fit a least squares regression
by regressing β̂kh(t) on h2. We denote the regression coefficient of h2 as Ĉk(t). Since the bias of
β̂kh(t) is on the order of h2, as shown in the asymptotic result,
∥∥∥Ĉk(t)∥∥∥h2 is an estimator for the
bias of β̂kh(t). Next we investigate the variability of β̂kh(t). We randomly split the data into two
equal parts. Using either one of the split data, we obtain β̂∗1kh(t) as the estimator for βkh(t) in this
case. Similarly, using the other half, we obtain β̂∗2kh(t). Thus, 14
∥∥∥β̂∗1kh(t)− β̂∗2kh(t)∥∥∥2 can be used as
an unbiased estimator of the variance of β̂kh(t). Finally, given all the time points, we select the
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∥∥∥β̂∗1kh(t)− β̂∗2kh(t)∥∥∥2 + ∥∥∥Ĉk(t)∥∥∥2 h4} .
(2.9)
We denote the optimal h1n as H1 and denote the corresponding estimators for βk(t) as β̂kH1(t).
Next, given h1n = H1 and βk(t) = β̂kH1(t), we select the optimal h2n, the bandwidth for estimating
σkl(t)’s, by minimizing the empirical mean squared error of the corresponding estimators, which is
numerically calculated in the similar way to above.
2.3 Theoretical Results
We first state the following required conditions.
Condition 1. True parameters λ0k(t), β0k(t), and σ0kl(t) are continuously twice differentiable for any
t ∈ [0, τ ], where k, l = 1, 2, . . . , p and k 6= l. In addition, λ0k(t) is strictly positive. Furthermore, the
second moments of Cov(dNik(t), dNik(s)|Xi)/dtds and temporal covariances Cov(εik(t), εil(s)) are
continuously twice-differentiable.
Condition 2. The vector of baseline covariate X is bounded. If there exists a vector b such that
XTb = 0, then b = 0.
Condition 3. h1n, h2n → 0 and nh1n, nh22n →∞. Furthermore, nh51n, nh62n → 0.
Condition 4. The kernel function K(z) is a symmetric density function satisfying
∫
z2K(z)dz <∞.
Similarly, K̃(z1, z2) is a symmetric bivariate density function with bounded fourth moments.
Condition 1 is used to give the asymptotic distribution for the parameter estimators in (2.1),
and it assumes some smoothness properties of the time-varying coefficients and covariance matrices.
From condition 3, the choice of h1n and h2n can be n−1/3 and n−1/4, respectively. A potential
choice of the kernel satisfying condition 4 can be the Gaussian kernel or the Epanechnikov kernel.
Theorem 2.3.1 states the asymptotic distribution of parameters β̂k(t), k = 1, 2, . . . , p. Theorem 2.3.2
establishes the asymptotic distribution of parameters σ̂kl(t), k, l = 1, 2, . . . , p, and k 6= l.



























where σ2(t,X, εk(t)) is a function of εk(t). Its definition and the proof of theorem 2.3.1 are given in
Appendix A.2.





→d N (0,Σkl(t)), (2.11)
where
Bkl(t) = λ0k(t)λ0l (t)E
[∫∫
g−1k (X
Tβ0k(t) + εk(t))g−1l (X












is assumed to be nonsingular, and the asymptotic variance
Σkl(t) = λ0k(t)λ0l (t)E
[









where ψ2(t, t,X, εk(t), εl(t)) is a function of εk(t) and εl(t). Its definition and the proof of theo-
rem 2.3.2 are given in Appendix A.3.
Since the asymptotic variances in theorem 2.3.1 and theorem 2.3.2 do not have simple expressions,
we use the bootstrap method to estimate the asymptotic variances in practice.
2.4 Simulation Studies
In the simulation studies, we simulated data of six health markers for 5,000 subjects. For the ith
subject, we generated two covariates Xi1 ∼ Uniform(−1, 1) and Xi2 ∼ Bernoulli(0.5)− 0.5. Thus,
Xi = (1, Xi1, Xi2)T was a three-dimensional vector of baseline variables. The maximum observation
time Ti for each subject was set to 12. The measured time points for simulated markers were generated
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from a Poisson process whose intensity function was E [dNik(t)|Xi] = 0.5 exp {0.5Xi1 + 0.25Xi2} dt.
For the variances of latent processes, we assumed ck = 1, k = 1, 2, . . . , 6. Suppose there were Ni
unique measured time points ti1, ti2, . . . , tiNi for all latent processes of the subject i, we sampled
εi(ti1), εi(ti2), . . . , εi(tiNi) from a mean-zero multivariate Gaussian distribution with a covariance
matrix Ω(ti) = Σ2(ti)⊗Σ1, where ti = (ti1, ti2, . . . , tiNi),
Σ1 =

1 0.34 0.48 0.58 0.03 0.05
0.34 1 0.80 −0.49 −0.78 0.80
0.48 0.80 1 −0.16 −0.36 0.53
0.58 −0.49 −0.16 1 0.80 −0.69
0.03 −0.78 −0.36 0.80 1 −0.85






1 e12 . . . e1Ni
e21 1 . . . e2Ni
...
... . . .
...
eNi1 eNi2 . . . 1

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, k, l = 1, 2, . . . , Ni. Thus, at each measured time point, Ω(t) is
constant and equals to Σ1, but there exist underlying dependencies in the time intervals between
these time points.
The values of simulated markers were generated according to (2.2) and (2.3). To assess the
ability of our models in Section 2.2.1 to handle mixed-type markers, we assumed Yi1(t) and Yi4(t)
were Gaussian distributed. Yi2(t) was Poisson distributed. Yi3(t), Yi5(t), and Yi6(t) were Bernoulli
distributed. Thus, g−11 (z) = g
−1
4 (z) = z, g
−1
2 (z) = ez, and g
−1
3 (z) = g
−1
5 (z) = g
−1
6 (z) = ez/(1 + ez).
Furthermore, since the distributions of Yi1(t) and Yi4(t) had dispersion parameters, we set φi1(t) =
φi4(t) = 0.5. The true values of (β1(t),β2(t),β3(t),β4(t),β5(t),β6(t)) were assumed to be































































Since the data-adaptive method for selecting bandwidths was computationally intensive, we first
conducted a preliminary study on the simulated data. We used the method in Section 2.2.4
and selected the optimal bandwidths among h = cn−1/z, where n = 5000, c = {5, 10, 20, 30},
and z = 1, 2, . . . , 10. Hence, the potential bandwidths ranged from 0.001 to 12.800. We found
h1n = 5n−1/3 = 0.292 and h2n = 10n−1/3 = 0.585 were close to the optimal. This set of h1n and
h2n was used in all subsequent simulations.
For time points t = 0, 1, . . . , 12, we solved (2.5) and (2.6), and we obtained β̂k(t) and σ̂kl(t). We
evaluated the accuracies of the asymptotic approximations by calculating the average bias and the
sample standard deviation of β̂k(t) and σ̂kl(t), respectively. In addition, using the bootstrap method,
we calculated the bootstrap estimators for standard errors of β̂k(t) and σ̂kl(t). Specifically, for each
dataset, we resampled 5000 observations with replacement from X to produce a bootstrap dataset
X∗1. We could use X∗1 to produce a new bootstrap estimator for βk(t), which we called β̂∗1k (t).
This procedure was repeated B times in order to produce B different bootstrap datasets, X∗1, X∗2,
. . . , X∗B, and B corresponding βk(t) estimators, β̂∗1k (t), β̂∗2k (t), . . . , β̂∗Bk (t). Next we computed
the sample variance of these bootstrap estimators and treated it as the estimated variance. Similar
procedures were also applicable to σ̂kl(t). Afterwards, 95% confidence intervals of each parameter
were constructed. Finally, we counted how many times true parameters βk(t) and σkl(t) fell in their
confidence intervals to obtain coverage probabilities.
Table 2.1 and Table 2.2 summarize the main results over 100 simulations at t = 1. From
Tables 2.1 and 2.2, we can conclude that, at t = 1, our method yields estimators β̂k(t) which are
close to the true parameters. All the estimators deviate from true parameters by less than 0.03.
On the other hand, the absolute values of biases between estimators σ̂kl(t) and true parameters
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become a little greater, but most of them are still less than 0.1. In addition, the bootstrap based
standard errors are reasonable estimators for the standard deviations of β̂k(t) and σ̂kl(t). Almost all
the differences between SD and SE are smaller than 0.03, except for σ̂34(t). Also, excluding σ̂13(t),
all the coverage probabilities are greater than or equal to 0.9, and the majority of them are around
0.95.
Table 2.1: Summary statistics for βk(t) at t = 1 based on 100 simulations.
Marker Parameter True value Bias SD SE CP
Y1 β10 -0.565 0.002 0.035 0.039 0.98
Continuous β11 0.933 0.001 0.059 0.067 0.98
β12 0.000 -0.002 0.085 0.078 0.94
Y2 β20 -0.819 0.007 0.050 0.058 0.98
Count β21 -1.030 0.026 0.112 0.112 0.95
β22 0.900 -0.010 0.117 0.132 0.97
Y3 β30 0.450 -0.006 0.074 0.077 0.94
Binary β31 -1.000 0.013 0.112 0.136 0.99
β32 0.900 0.011 0.157 0.151 0.93
Y4 β40 -1.260 -0.006 0.038 0.039 0.93
Continuous β41 0.982 -0.010 0.063 0.068 0.97
β42 0.765 -0.005 0.078 0.077 0.93
Y5 β50 0.732 0.001 0.077 0.074 0.95
Binary β51 0.470 0.001 0.149 0.134 0.92
β52 0.315 -0.014 0.163 0.150 0.92
Y6 β60 0.331 -0.018 0.085 0.077 0.90
Binary β61 0.100 0.004 0.144 0.136 0.95
β62 1.924 -0.021 0.163 0.156 0.94
Note: “Bias” is the bias of the average estimates; “SD” is the sample standard deviation of the
estimates; “SE” is the average of the estimated standard errors based on 100 bootstrap samples;
“CP” is the coverage probability of the 95% confidence intervals.
After examining the estimators at a fixed time point, we also investigated the estimation
performance as time changes. For instance, Figure 2.2 presents true parameters vs estimators across
the 13 time points for β52(t) and σ34(t), respectively. From Figure 2.2, we can conclude β̂52(t) is
very close to the true parameter at each time point, and it well captures the underlying smooth
function of β52(t) across time. Although the bias between σ34(t) and σ̂34(t) is greater than that
between β52(t) and β̂52(t), all of σ34(t) are in the interquartile range of σ̂34(t). Thus, the estimators




















































Average estimator True value
(b)
Figure 2.2: Top panel: true β52(t) versus β̂52(t) across 13 time points based on 100 simulations.
Bottom panel: true σ34(t) versus σ̂34(t) across 13 time points based on 100 simulations. Red
triangles: true values of the parameter. Blue triangles: average estimators of the parameter. Red
curve: the true function of the parameter.
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Table 2.2: Summary statistics for σkl(t) at t = 1 based on 100 simulations.
Parameter True value Bias SD SE CP
σ12 0.342 -0.061 0.149 0.136 0.91
σ13 0.484 -0.058 0.202 0.213 0.98
σ14 0.578 -0.086 0.127 0.121 0.87
σ15 0.034 0.030 0.216 0.218 0.95
σ16 0.047 -0.009 0.210 0.207 0.96
σ23 0.799 -0.150 0.388 0.382 0.90
σ24 -0.493 0.065 0.232 0.233 0.95
σ25 -0.779 0.078 0.241 0.242 0.94
σ26 0.796 -0.143 0.371 0.366 0.91
σ34 -0.163 0.048 0.216 0.252 0.97
σ35 -0.363 -0.024 0.252 0.261 0.97
σ36 0.530 -0.024 0.257 0.249 0.95
σ45 0.802 -0.076 0.212 0.219 0.94
σ46 -0.686 0.089 0.228 0.244 0.94
σ56 -0.846 -0.019 0.160 0.181 0.97
Note: “Bias” is the bias of the average estimates; “SD” is the sample standard deviation of the
estimates; “SE” is the average of the estimated standard errors based on 100 bootstrap samples;
“CP” is the coverage probability of the 95% confidence intervals.
2.5 Real Data Application
2.5.1 Data Prepocessing
We applied the proposed method to analyze EHRs of T2D patients from the OSU-WMCIW. In
our application, we included three baseline variables Xi: baseline age, race (1: white; 0: non-white),
and sex (1: male; 0: female). Besides, there were five health markers Yik(t) related to T2D: HBP,
TC, HbA1c, HDL, and medications prescribed at each clinical encounter. Here, we dichotomized
HBP as HBP=1 if a patient’s systolic blood pressure is higher than 140 mmHg and 0, otherwise.
The medications served as one strong indicator of patient’s comorbidity and they could be T2D
related or not. Thus, the health markers in the analysis consisted of three continuous markers (TC,
HbA1c, HDL), one binary marker (HBP) and one count marker (number of medications).
For analysis, we split the data into three parts for different purposes. The first data consisted of
the records collected between 2011 and 2012 and was used to estimate the variances of individual
latent processes by fitting univariate generalized linear mixed models. The second part included the
records from 24,975 patients between 2013 and 2017 who had at least one marker measurement.
This part of the data was used for training our models and learning latent groups among the
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patients. The third part was the data collected in 2018 and would be used for validation purpose.
The flow-chart for this application is illustrated in Figure 2.3.
Dataset Workflow Method 
Estimate the variance for each latent 
Gaussian process, 𝑐𝑘.
Estimate the parameter for the intensity of 
each health marker, 𝛾𝑘 .
Andersen-Gill model.
Generalized linear mixed-effects model. 2011-2012 EHRs
2013-2017 EHRs
Estimate the regression coefficient for each 
health marker, 𝛽𝑘(𝑡).
Kernel weighted smoothing, method of moments, 
Gauss-Hermite quadrature.
Estimate the correlation coefficient each pair 
of health markers, 𝜎𝑘𝑙(𝑡).
at 61 points
𝑡1 = 1 (day). The other time points are the time 
differences (in days) between the last day of each 
month in the five-year window and 12/31/2012.
Compute the similarity between each pair of 
subjects, 𝐷𝑖𝑗 .
Mahalanobis distance, Gauss-Hermite quadrature.
Identify patient subgroups. Clustering analysis, dendrogram.
Validate the identified patient subgroups.
Average value of the normalized health markers for 
each patient group. 2018 EHRs
Figure 2.3: Flow-chart of the proposed analysis framework of EHRs to dissect patient heterogeneity
using a diverse set of health markers.
In our model fitting using the second part of the data, after checking normal ranges for the
health markers (Stone et al., 2014; Whelton et al., 2018; American Diabetes Association, 2018), we
removed extreme records such as TC ≤ 0 or ≥ 500 mg/dL, HbA1c ≤ 3 or ≥ 20%, and HDL ≤ 0 or
≥ 120 mg/dL. This led to a deletion of 1% of the data and a total number of 24,655 patients for
analysis. Among these patients, 52.08% were female, 63.42% were white, and their ages in years
ranged from 18.30 to 97.67 with a mean of 56.06. All of them had at least one observation for at
least one health marker in the 5 years, but not necessarily for other health markers. Specifically, the
average numbers of records for HBP, TC, HbA1c, HDL, and the number of medications per patient
during these 5 years were 17.50, 4.01, 5.95, 3.64, and 53.21, respectively. In order to minimize the
influence of different scales on the numeric stability, we normalized all continuous variables before
identifying patient subgroups. Each of them has zero mean and unit variance.
2.5.2 Results
Table 2.3 shows the effect of each demographic variable on the pattern of the measurement times
for each marker. From Table 2.3, we conclude that elder patients tend to have more observations
for all health markers and females appeared to have more observations for HBP, HbA1c, and the
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number of medications, while males tend to have more TC measurements. Finally, whites have
significantly less observations for HBP, HbA1c, and the number of medications than non-whites.
Table 2.3: Effects of demographic variables on the frequency of health marker measurements
Marker Demographic Est HR SE Z P-value
HBP age 0.065 1.067 0.006 10.552 < 0.001
sex 0.064 1.066 0.013 4.813 < 0.001
race -0.129 0.879 0.014 -9.425 < 0.001
TC age 0.035 1.035 0.006 6.238 < 0.001
sex -0.035 0.965 0.012 -3.000 0.003
race -0.012 0.988 0.013 -0.968 0.333
HbA1c age 0.008 1.008 0.005 1.721 0.085
sex 0.034 1.034 0.009 3.678 < 0.001
race -0.044 0.957 0.009 -4.650 < 0.001
HDL age 0.047 1.048 0.005 10.090 < 0.001
sex -0.010 0.990 0.010 -1.007 0.314
race -0.007 0.993 0.010 -0.715 0.475
Medications age 0.042 1.043 0.006 7.262 < 0.001
sex 0.086 1.090 0.012 7.069 < 0.001
race -0.113 0.893 0.013 -8.988 < 0.001
Note: “Est” is the regression coefficient estimator; “HR” is the hazard ratio; “SE” is the standard
error of the coefficient estimator; “Z” is the statistic for a z-test; “P-value” is the p-value for the
z-test.
To estimate the parameters in the joint models, we first implemented the adaptive method of
bandwidth selection as stated in Section 2.2.4, and results are shown in Figure 2.4. We ended up to
choose h1n = 564.112 days and h2n = 494.687 days as the optimal bandwidths. Using the optimal
bandwidths, we estimated βk(t) and σkl(t) at 61 time points. The results are presented in Figure 2.5
and Figure 2.6, respectively. The salmon-colored ribbons in these two figures are 95% confidence
intervals for the parameters based on 100 bootstrap datasets.
Figure 2.5 presents the relationships between each pair of health markers and covariates. In
general, all health markers exhibit changes over time. Mean HbA1c (β̂30(t)) decreases during the
first 1.5 years and has an increasing trend afterward, which may suggest the difficulty to achieve
long-term control of glycemic levels in a chronically ill patient population. Mean HDL (β̂40(t)) shows
a similar quadratic pattern over time, suggesting difficulty of long-term TC control. The estimated
regression coefficients for covariates, i.e., the estimated effects of covariates on health markers, do not
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vs. h1. The optimal h1n = 564.112 days. (b): the plot for
∑
t MSEh2σ (t) vs. h2. The optimal
h2n = 494.687 days. Red triangles: optimal bandwidths.
around mean values. However, we can observe decreasing trends for β̂20(t) and β̂50(t), suggesting
that as time increases, the expected means of TC and the number of medications decrease. β̂11(t)
and β̂41(t) are positive across time, while β̂21(t) and β̂31(t) are negative. β̂51(t) is negative but close
to 0. Hence, estimators β̂·1(t) suggest that elder subjects on average have higher HBP and HDL,
but they have lower TC and HbA1c. There is no apparent difference in the average number of
medications between elder subjects and younger subjects. Similarly, estimators of sex effect, β̂·2(t),
suggest that compared with men, women tend to have higher expected means of TC and HDL, but
they have lower values of HBP and the number of medications. Although women have slightly lower
expected means of HbA1c than men, the difference is inapparent. For race, the estimators of β̂·3(t)
indicate that white people have lower or equal expected means than non-white people in almost all
five health markers.
Figure 2.6 presents the correlations between each pair of health markers. The results suggest
the concurrent correlations between HBP and TC, HBP and medications, TC and HbA1c, TC
and HDL are positive and moderate. Moreover, there exist negative and observable concurrent




































































































































































































































































































































Figure 2.5: Estimated regression coefficients β̂k(t) across 61 time points using h1n = 564.112 days
and h2n = 494.687 days from EHRs at the OSU-WMCIW. Salmon-colored ribbons: 95% confidence




































































































































































































































































































Figure 2.6: Estimated correlations σ̂kl(t) across 61 time points using h1n = 564.112 days and
h2n = 494.687 days from EHRs at the OSU-WMCIW. Salmon-colored ribbons: 95% confidence
intervals for the estimators.
23
and HDL decreases as time increases. On the opposite, the positive correlation between TC and
HDL decreases at the beginning, but increases after about 1 year. The positive correlation between
TC and HbA1c has a similar pattern as it decreases at first and increases after 1000 days. The
correlations of HBP and TC, HbA1c and number of medications increase in first 500 days, but they
start to decrease during 500 to 1000 days, and bounce back afterward. The correlations of HBP
and HbA1c, HBP and HDL, HDL and number of medications decrease in first 500 days, and then
increase, but decrease again after 1000 days.
One interesting observation from Figure 2.6 is that the estimated correlation between the number
of medications and HBP is as high as 0.6 but its correlations with TC and HDL are both negative,
fluctuating around -0.30. However, there does not appear to be a strong association between the
number of medications and HbAc1 over time. This may suggest that the patients in this cohort
were most likely to take medications that aimed to control the levels of TC and HDL, but not
necessarily for controlling the level of HbA1c. The latter is consistent with the fact that over
90% of drugs recorded in this database are non-diabetic drugs. One possible interpretation of the
observed time-dependent correlation pattern is that there might exists another unobserved disease
health marker that influences the two observed markers temporally. Thus, the estimated correlation
pattern could be potentially useful to identify such “common cause” health markers so as to better
understand the mechanism of disease progression.
Finally, we computed the similarity between each pair of patients using the distance defined
in (2.7). To compute ε̂i(t) as (2.8), we substituted Ŷi(t) with the nearest neighbor observation of
time t for patient i. Using the between-patient similarity matrix, we performed a cluster analysis on
the 24,655 patients, and the results are given in Figure 2.7. We observed 4 clusters within which
patients had similar health marker profiles.
To better understand the health patterns of patients in each subgroup, we calculated the average
of normalized measurements for each health marker in each group, as shown in Figure 2.8. In the
top panel of Figure 2.8, the value in each cell is averaged over all patients and all clinical encounters
between January 1, 2013 and December 31, 2017. We compared these values to the average of each
health marker in the entire study sample. A higher value of HDL and a lower value of HBP, TC,
and HbA1c represent healthier T2D status. The number of medications prescribed at each clinical
encounter does not directly reflect the disease status, but a lower count usually indicates a less
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Figure 2.7: Dendrogram of Mahalanobis distances for 24,655 patients at the OSU-WMCIW. Group
index numbers are assigned according to group sizes.
severe state. Group 4 contains 2,163 patients, whose TC was slightly higher than the overall average.
Their HBP, HDL, and the number of medications were lower than the overall averages. In addition,
they had the highest HDL and it was substantially higher than the overall average. Thus, group 4
is the relatively healthy group in which patients did not take many medications. Group 1 contains
10,705 patients who were less healthy since they had lower-than-average HDL, but other health
markers were favorable or roughly neutral. The TC of 6,930 patients in group 2 was higher than the
overall average, while other health markers were lower or around the averages. We conclude that
group 2 is a moderately ill group. For the 4,857 patients in group 3, their TC levels were slightly
lower than the overall average, however, they had the highest HbA1c. Also, other markers indicated
bad health status. Therefore, group 3 patients were in the most severe state of T2D.
To examine whether the subgroups inferred by the clustering truly represent patients health
profiles, we validated the detected patterns using the third fold of the split data that consisted of
the EHR data collected after January 1, 2018. These data were not used in any other analyses of
this application. The average values of normalized measurements for each health marker in each
group are shown in the bottom panel of Figure 2.8. We conclude that the patients health patterns
identified prior to year 2018 are consistent with those patterns afterward. Therefore, the patient
groups are not only meaningful, but also represent some true underlying patient patterns over time.
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Figure 2.8: Averages of normalized measurements by health markers and patient subgroups. (a):
using data from 1/1/2013 to 12/31/2017. (b): using data after 1/1/2018. Red: more severe status
than the overall sample average in terms of a health marker; blue: healthier status than the overall




In this chapter, we proposed a latent temporal process model to integrate health markers
in EHRs and characterize patient heterogeneities. The proposed method is capable of handling
unbalanced records and informative visits, that is, patients can have missing health markers at some
encounters or with visit times depending on their health status. Additionally, our model can both
fit different types of health marker, capture the dependence structures among health markers, and
takes into account informative patterns of visit times, via the intensity function of health markers.
The real data application shows the capability of the proposed method on addressing the data
challenges of EHRs, integrating different types of health markers, and identifying meaningful and
robust patient subgroups. Therefore, the proposed method may shed lights on the detection of
patient homogeneities and heterogeneities, and serve as a step towards applications of personalized
medicine.
In the parameter estimation process, we assumed that variances of the latent variables εi(t)
were fixed and they were estimated using the EHR data of 2011 and 2012. To study whether
the constant variance was reasonable, we estimated the changes in variances from six different
time periods in windows of 2 years as well as using the whole 5-year data, and the results, as
shown in Tables A.1 and A.2, indicate that the estimates varied little. Thus, the constant variance
assumption seems to be reasonable for our application. In addition, we re-estimated βk(t) and σkl(t)
using the same proposed parameter estimation approach but with the 5-year variance estimates
in Table A.2. Figures A.1 and A.2 reveal slight changes in the estimated coefficients. In fact, the
absolute percentage changes between the two sets of coefficients are less than 1%, except for β̃1·(t)
and σ̃1·(t) which have changes of up to 3%. Therefore, we could conclude that the estimation results
are robust to the constant variance estimates.
Moreover, to investigate the effect of bandwidth selection on parameter estimation, we report
βk(t) using two suboptimal bandwidths that are close to the optimal bandwidth in Section 2.5.2.
Figure A.3 shows that the suboptimal estimators preserve the similar pattern to β̂k(t). The Canberra
distances (Lance and Williams, 1966) between the optimal estimators and suboptimal estimators of
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is the vector of these estimators using a suboptimal bandwidth H ′1. Most of the distances
are as smaller than 0.05 as given in Table A.3, confirming the estimates using the optimal and
suboptimal bandwidths are close. The conclusions could also be drawn for estimating σkl(t) (cf.
Figure A.4 and Table A.4).
In our models, we assumed that the intensity function of the counting process only depended
on the baseline covariates. This assumption can be violated if the intensity also depends on the
historical marker values. However, directly incorporating time-dependent marker values, which are
missing for most of time points, is challenging. To examine how this assumption may affect our
results, we included an ad hoc marker value, defined as the mean value of HbA1c in the past 12
months, in the intensity model (2.1). From Table A.5, the effects of the historical HbA1c level
on frequencies of HBP, TC, and HbA1c are significant, while the historical HbA1c level has lower
impacts on frequencies of HDL and the number of medications. Figures A.5 and A.6 also reflect
this phenomenon that there are slight differences between two versions of estimators for HDL and
the number of medications. Although differences between two versions of estimators for HBP and
TC are moderate, the new estimators still locate within or around the 95% bootstrapped confidence
intervals for the original estimators. However, for HbA1c, the differences could not be ignored
since the estimated curves present some unusual shapes. Therefore, further investigation is needed
regarding what time-dependent marker values should be used and how missing data issues should
be addressed.
As stated in Section 2.1, the latent processes can be also viewed as projections of the health
markers onto a lower dimensional space. Therefore, our method can be used for identifying latent
clusters among patients as illustrated in our application, and at the same time can also play a role
in learning personalized disease prognosis and personalized disease management. For example, the
summary of latent processes can be used to improve the understanding of treatment propensity
scores in EHRs when learning individualized treatment rules. Lastly, the latent processes can be
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included in disease outcome models as prognostic or predictive health markers, and we will show
this extension in Chapter 3.
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CHAPTER 3: ESTIMATING INDIVIDUALIZED TREATMENT RULES FOR
MULTICATEGORY TYPE 2 DIABETES TREATMENTS USING
ELECTRONIC HEALTH RECORDS
3.1 Introduction
T2D is the most common type of diabetes which causes millions of people to suffer from severe
diabetes-related complications such as heart attacks, stroke, blindness, and kidney failure (Roglic,
2016). To treat T2D, American Diabetes Association (2018) recommended to use metformin
monotherapy as the initial treatment and select additional therapies based on patient-centered
considerations. A treatment guideline from the United Kingdom also suggested metformin as the
first-line drug, unless it is contraindicated or not tolerated (McGuire et al., 2016). Palmer et al.
(2016) summarized 301 clinical trials (1.4 million patient-month) in which metformin and other 8
available classes of glucose-lowering drugs were compared. This meta analysis reported that when
compared with other drugs given as monotherapy, metformin only had better or similar effects on
managing HbA1c levels among adults with T2D. Nevertheless, there was no significant difference in
all-cause mortality or other complications between any glucose-lowering drugs alone or combined.
There is a lack of conclusive evidence for the best T2D management strategy from clinical trials.
With the emergence of large-scale electronic systems such as EHRs, which usually contain patient
demographics, vital signs, laboratory test results, medications, diagnosis, and medical insurances
documented at the point of care, there has been an increasing trend of using EHRs as an observational
database to study T2D treatment patterns in real world practices. For example, Montvida et al.
(2018) selected 1.02 million adults with T2D from the U.S. Centricity Electronic Medical Records
and concluded that, from 2005 to 2016, first-line use increased for metformin (60% to 77%) and
decreased for sulfonylureas (20% to 8%). Canivell et al. (2019) used a 5-year-EHR for 15,205 patients
with T2D from the SIDIAP database and assessed glycemic controls after treatment intensification.
Compared to experiments such as RCTs, observational studies use real-world information from
larger patient populations and contain a longer duration of observations, and thus may offer valuable
complements to RCTs. Studies using large-scale EHRs may reflect real-world patterns of treatment
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pathways which can neither be conducted nor observed in RCTs (Hripcsak et al., 2016). More
importantly, EHRs provide a great opportunity to study the heterogeneity of treatment responses in
a large population so that we can learn optimal ITRs for T2D patients to fulfill the goal of precision
medicine, a medical paradigm that utilizes individual patient’s characteristics such as demographics,
lab test results, and genetic information, to optimize treatments (Ginsburg and Phillips, 2018).
There has been intensive methods development for precision medicine in the fields of statistics
and machine learning over the last decade (Mesko, 2017). These methods include regression model-
based methods such as Q-learning (Watkins and Dayan, 1992; Murphy, 2005; Qian and Murphy,
2011), A-learning (Murphy, 2003; Robins, 2004), regret-regression (Henderson et al., 2010), and
subgroup analysis (Foster et al., 2011; Lipkovich et al., 2011; Fu et al., 2016). Through directly
optimizing ITR-related value functions, Zhao et al. (2012) proposed an outcome weighted learning
approach that converted the estimation of ITRs to a weighted classification problem. Similar
methods were later developed in contrast weighted learning (Tao and Wang, 2017) and augmented
outcome weighted learning (Liu et al., 2018). More recently, Wu et al. (2020) proposed a matched
learning approach, called M-learning, to learn ITRs based on pairs of patients who shared similar
pre-treatment health profiles. This approach was demonstrated to be more robust than weighting
methods.
However, the above methods are confronted by the following challenges when applied to EHRs.
First, characterizing individual patient’s pretreatment condition is difficult since their health
markers measured over time are multivariate and the measurements can be continuous (e.g., lab
measures), binary (e.g., disease diagnoses) or counts (e.g., number of medications). Moreover, these
measurements are taken at patient’s clinical encounters which potentially depend on their underlying
health status. Thus, not accounting for informative measurement patterns of health markers may
cause selection bias (Haneuse, 2016; Haneuse and Daniels, 2016). Second, there are often many
observed treatment options and patient’s propensity to receive one specific treatment is complex
and heterogeneous, which may not be captured by parametric models. Furthermore, there presents
substantial heterogeneity among patients in terms of treatments and outcomes that need to be
accounted for when learning ITRs. Standard weighting methods suffer from numerical instability
due to low representation of patients with some treatments.
In this chapter, to address the challenges in EHRs, we propose a general framework for learning
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ITRs for T2D patients and use one concrete dataset as an example to demonstrate the framework.
Specifically, we propose a multivariate longitudinal model to model the time-trajectory of different
types of health markers through a generalized exponential family of distributions, while accounting
for their dependence through a latent multivariate Gaussian temporal process. We also adopt inverse
intensity weighting to adjust for potential informative times of measurements. Through the joint
models, we can identify several T2D patient subgroups using clustering algorithm to summarize
patients’ health profiles based on their pre-treatment EHRs. To learn ITRs within each subgroup,
we create a few classes of treatments and apply nonparametric methods to estimate treatment
propensity scores. Finally, to handle the challenge of multiple treatments, we extend matched
learning method in Wu et al. (2020) to multicategory treatments. Particularly, we develop an
one-versus-one matched learning method to estimate ITRs. The derived rules are further validated
through cross-validation.
The remaining part of this chapter is organized as follows. In Section 3.2, we provide the details
of the proposed models and learning methods. In Section 3.3, we demonstrate an implementation of
our methods to EHRs from the OSU-WMCIW. In Section 3.4, we describe the estimated ITRs for
T2D patients and compare with the observed treatments in EHRs. Concluding remarks are given in
Section 3.5.
3.2 A General Framework to Learn Optimal ITRs Using EHRs
We use A, Z, and R to denote a T2D patient’s treatment at a decision time (referred to as
time zero), pre-treatment features, and reward outcome, respectively. We assume no unobserved
confounding and stable unit treatment value assumption, which are two crucial assumptions to allow
using the EHRs for learning the optimal treatment rules. The first assumption implies that the
treatment assignment is independent of potential outcomes given Z, so there will not be any hidden
bias due to unobserved confounding; while the second assumption implies that there is no treatment
interference between the patients. The assumptions are not testable due to the observational nature
of the EHRs but may be plausible if Z contains sufficient information about why each patient
received one particular treatment and one patient’s response does not depend the other patients’
treatments or responses. Under these assumptions, it is known that the optimal ITR is a function
mapping Z to A’s domain and it is given as the treatment that yields the maximum value of
E (R|Z, A = a). Many methods have been developed to estimate such optimal ITR using RCTs,
32
but our goal is to instead use EHRs to estimate the optimal ITR.
Data from EHRs consist of patient’s health marker measurements, for example, body mass index
(BMI), cholesterol level, and HbA1c for T2D patients, as well as received medications, at clinical
encounters over a span of calendar time windows. Time zero is usually set to be the index date when
a patient received treatment A, and the reward outcome, R, is a pre-defined measure indicating
disease improvement since time zero (for example, HbA1c reduction within 6 months after taking the
treatment). However, obtaining a reasonable set of feature variables for Z is challenging, since they
not only include patient’s demographics (age, gender, race), but more importantly, should reflect
patient’s preconditions that are useful for the treatment decision. The latter must be extracted
from patient’s longitudinal health markers before time zero.
In the following sections, we first extend the method in Chapter 2 to extract patient’s pre-
treatment health profiles using EHRs that will be included as feature variables for learning ITRs.
We then propose a matching-based learning algorithm to estimate optimal treatment rules that will
maximize patient’s outcomes.
3.2.1 Characterizing Patient’s Pre-treatment Health Conditions
Given the heterogeneity among patients in EHRs, it is important to characterize patient’s
pre-treatment conditions based on longitudinal marker measurements in EHRs. We present methods
to handle two challenges: the first challenge is that patterns of measurement time points may depend
on patients’ underlying health status and thus are informative; the second challenge is that health
markers are of mixed types and collected at different time points.
We use the same notations of n, p, Xi, Yik(t), and Nik(t) as those in Section 2.2.1. However, in
this framework, we extend the equation (2.1) to





where λk(t) is a baseline intensity function, Lik(t) is a vector of observed health history up to time
t, and γk and ηk are intensity parameters. For example, in real data, Lik(t) can take the value of
average blood pressure measurements in past 3 months, and a patient with higher blood pressures
is likely to have a revisit in a shorter time than a patient with normal blood pressures. This effect
is measured by the intensity parameter ηk. We still assume Yik(t) follows a generalized exponential
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family model as (2.2). Also, the regression coefficients βk(t) and the covariance matrix Ω(t) are
defined and modeled as (2.3).
The parameters in the intensity model for Nik(t) can be estimated by fitting a standard
Andersen-Gill proportional intensity model. We denote the coefficient estimators as γ̂k, and η̂k. To
estimate the parameters in model (2.3) and further account for irregular time intervals, we define




, and then we solve the following kernel-weighted local







Kh1n(s− t)Xi[Yik(s)− Eik(t)]dÑik(s) = 0, (3.2)




XTi βk(t) + εik(t)
) ∣∣∣Xi], Kh(u) = K(u/h)/h with K(u) being a symmetric
kernel function, usually taken to be the Epanechnikov kernel or Gaussian kernel, and h is its
bandwidth.
Denote the estimators obtained by solving (3.2) as β̂k(t). Similarly, for each element in









dÑik(s)dÑil(s′) = 0, (3.3)









XTi β̂l(t) + εil(t)
) ∣∣∣Xi] ,
and K̃h(u1, u2) = K̃(u1/h, u2/h)/h2. Here, K̃(u1, u2) is a bivariate kernel function, usually taken to
be the product of univariate Epanechnikov or Gaussian kernel, and h is its bandwidth. Denote the
estimators as σ̂kl(t). Unlike (2.6), in this case, we estimate the diagonal elements of Ω(t) directly
from the data instead of historical records or external resources. The bandwidths in the estimating
equations (3.2) and (3.3) are determined using the same approach in (2.9). In Appendix B.1, we
provide numerical evidence through a simulation study to demonstrate the good performance of the
proposed estimation method.
Finally, to characterize patient’s pre-treatment health status into clusters where patients within
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the same cluster share similar health profiles, we compute the similarity distance between each pair
of patients as (2.7), and then we perform a hierarchical clustering based on the distance matrix.
Because the Mahalanobis distance naturally accounts for the between-marker correlation, the use of
such distance can effectively remove the redundant information regarding the patient’s health status.
We choose the hierarchical clustering because it is a powerful approach to identify homogeneous,
interpretable groups of the patients. Thus, even though the original heath markers are measured
irregularly and are of very different data types, our joint models enable one to combine them using
the latent processes on the same scales and account for dependence over time. With the estimated
subgroups from clustering, the subsequent ITRs will be estimated for each subgroup separately.
3.2.2 Matched Learning for Multicategory Treatments
When estimating ITRs for binary treatments, Wu et al. (2020) showed that M-learning could
outperform other commonly used methods for observational databases. Thus, we generalize M-
learning to handle multicategory treatments which are commonly seen in EHRs. First, in each
patient subgroup s ∈ {1, . . . , S} that was identified before, the comparison among a total of K
treatments can be converted to K(K − 1)/2 comparisons between two treatments, which can be
integrated using the one-versus-one method to yield an optimal ITR for all treatments.
Specifically, for each patient i in each subgroup s, let Zi denote the baseline covariates Xi and
some additional pre-treatment health marker information, for example, the average BMI in the
past year. We let Ai and Ri be the treatment at time zero and the reward outcome post-treatment.
For each treatment pair (u, v), let Ti = 1 if Ai = u and Ti = −1 if Ai = v. Assume there are
N su,v patients who received treatment u or v in group s. Antonelli et al. (2018) and Wu et al.
(2020) proposed a doubly robust matching method to improve the efficiency of matching methods.
This method uses not only covariates but also propensity scores and prognostic scores, denoted by
π(Zi) ≡ P (Ti = 1|Zi) and ψ(Zi) ≡ E [Ri|Zi], respectively, to create matched sets. Thus, for the ith
patient, the improved matched set, denoted by Mis, has an expression as follows:
Mis = {j : Aj 6= Ai, d(Hj ,Hi) ≤ δ} ,




, and δ is a threshold which may vary
with i. In our implementation, we use random forests (Ho, 1995) to perform a multicategory
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classification for Ti given Zi to obtain π̂(Zi) and use gradient boosting machines (Friedman, 2001)
to estimate Ri given Zi to obtain ψ̂(Zi). As suggested by Antonelli et al. (2018) and Wu et al.
(2020), the doubly robust method may lead to the optimal treatment rules even if the model for the
propensity score, or the model for the prognostic score is misspecified, but not both, and including
prognostic scores was empirically shown to perform better than the methods without using them.
Following Wu et al. (2020), we adopt a weighted SVM (Cortes and Vapnik, 1995) with weights
for estimating ITR when comparing treatments u and v. Specifically, we minimize the following
objective function







×φ (−f(Zi)Tisign(Rj −Ri)) + λsu,v ‖f‖Hk , (3.4)
where φ(x) is the hinge loss given by max(1− x, 0), f(·) is a function such that the decision rule
D(Z) = sign(f(Z)), |Mis| is the size of matched set Mis, λsu,v is a tuning parameter, and Hk is a
reproducing kernel Hilbert space with a kernel function k(·, ·). Using the weight |Rj −Ri| ensures
that the estimated treatment rule is driven by comparing the pairs of patients who have large
outcome differences. Using a weighted SVM to minimize V su,v(f ; g), we obtain the optimal ITR,
D∗su,v, for comparing treatment u to v in group s. Similarly, for the remaining treatment pairs, we
estimate the corresponding decision rules. Therefore, for the ith patient in group s, we derive the
optimal ITR, D∗s(Zi), as the majority vote recommended by
{
D∗su,v(Zi) : u, v ∈ {1, . . . ,K} , u 6= v
}
.
In the above learning algorithm, the tuning parameters are chosen using cross-validation. The
ITRs estimated from a training sample (i.e., D̂∗s(·)) are evaluated using an independent testing




i∈test sample I(Ai = D̂∗s(Zi) = u)Ri/P̂ (Ai = u|Zi)∑K
u=1
∑
i∈test sample I(Ai = D̂∗s(Zi) = u)/P̂ (Ai = u|Zi)
, (3.5)
where P̂ (Ai = u|Zi) is the estimated probability of Ai = u from the propensity score estimation.
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3.3 Implementation Using OSU-WMCIW EHRs
3.3.1 Data Preparation
The EHRs from OSU-WMCIW contain demographics, laboratory test measures, vital signs, and
diagnosis codes for 58,490 patients diagnosed with T2D between 2011 and 2018. We set time for
the treatment decision for each patient (time zero) as the last clinical encounter in year 2016 when
he or she received T2D medications. This choice was based on two facts in order to learn ITRs
from data with limited time periods: we needed a sufficient time window of the longitudinal history
before time zero to precisely characterize patient’s health status and subgroups; and we needed a
reasonable follow-up period after time zero to precisely calculate the outcome variable, the HbA1c
level at 6 months after time zero.
In the EHRs, there were four health markers Yik(t) associated with T2D: systolic blood pressure
(SBP), HbA1c, HDL, and BMI. After checking normal ranges for the health markers (Stone et al.,
2014; Whelton et al., 2018; American Diabetes Association, 2018), we removed missing, duplicated,
and extreme entities such as SBP≥250 mmHg, HbA1c≤3 or ≥20 %, HDL≤0 or ≥120 mg/dL, and
BMI≤10 or ≥60 kg/m2. In addition, we created a binary variable to denote whether diabetic drugs
were prescribed at a clinical encounter (DD) and a continuous variable as the logarithm of the
number of medications prescribed at each encounter (logMed). Both variables were considered as
an important indication of T2D patient’s comorbidity status. Therefore, our analysis included one
binary longitudinal marker and other 5 continuous health markers over time (SBP, HbA1c, HDL,
BMI, logMed). We require that at least one measurement for at least one marker is available before
time zero. With this restriction, there were a total of 8,456 subjects with 497,763 longitudinal
records before time zero date and they were used to learn patient’s pre-treatment subgroups using
the method in Section 3.2.1. Among these patients, 53.43% were female, 62.03% were white, and
their ages in years ranged from 17.89 to 100.84 with a mean of 59.67. The number of records for
SBP, HbA1c, HDL, BMI, and DD was 9.8, 2.3, 4.0, 2.2, 14.6, and 29.3, respectively, when averaged
all the patients.
The medications at time zero were considered to be treatments, Ai, for learning ITRs. There
were 3,978 types of medications observed in the EHRs, and we classified the medications to either
the 163 diabetic drugs for T2D (Drugs.com, 2019) or the remaining non-T2D medications before
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further grouping them. As stated in Section 3.1, metformin is commonly considered as the first-line
drug for T2D and it may have a better control of HbA1c levels than other T2D drugs given as
monotherapy. On the other hand, there is some evidence that basal insulin also serves as an
important T2D treatment. Thus, we compared four classes of treatments: metformin monotherapy,
insulin monotherapy, other T2D monotherapy or combinations of other T2D drugs, and combinations
of at least two classes of treatment among the aforementioned three classes. We referred the third
class as “other T2D drugs” and the fourth class as “multiple T2D drugs”. Thus, Ai was one of four
treatments including metformin, insulin, other T2D drugs and multiple T2D drugs.
We were interested in the treatment effects on reducing HbA1c level after time zero. For the
ith patient, we constructed the outcome variable Ri as the expected HbA1c level 6 months after
the date of time zero. In particular, we first collected all available HbA1c measures from lab tests,
which were conducted from time zero to up to one year after. For each patient, we performed a
linear interpolation model as αi + βi(tij − ti,baseline), where tij was the date (in years) for the jth
measurement for patient i, ti,baseline was the date for time zero, and αi and βi were respectively the
intercept and slope for the patient’s trajectory. Finally, based on the least-square estimates, we
defined the outcome as the expected HbA1c level at 6 month after treatment for each patient, which
was given as Ri = α̂i + 0.5β̂i. In OSU-WMCIW data, only 5,458 patients had at least two HbA1c
measurements during the year after time zero so their outcomes could be calculated. Furthermore,
we excluded 333 patients whose estimated slope coefficient was either greater than 5 or less than
−5, which were not sensible clinically.
To construct the feature variables, Zi, we first used the proposed method in Section 3.2.1 to
obtain subgroups of all patients using all available heath markers before time zero. More specifically,
when fitting the joint models, the covariates entering the intensity models (3.1) for the measurement
times included the demographics and time-dependent covariates indicating whether there was any
measurement of longitudinal marker k in the past 6 months and if there was, what was the average
marker value. Using about 2-year data prior to time zero, we estimated the intensity parameters
γk and ηk, along with βk(t) and Ω(t) at 25 equally spaced time points (in days), where the time
length between two consecutive time points were 30 days. Given β̂k(t) and Ω̂(t), in this particular
application, we integrated health markers over time by calculating ε̂i(t) through the 20-point
Gaussian quadrature. Using the between-patient similarity matrix, we performed a hierarchical
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clustering analysis on all 8,456 patients. Appendix B.2 presents parameter estimation and clustering
analysis results on identifying patient subgroups.
The derived groups using our models represented patient’s chronic preconditions so might not
capture patient’s most recent health status before the treatment. Therefore, we also included in Zi
the average values of the heath markers during the most recent year before time zero. Consequently,
Zi consisted of the derived group membership, the average values of SBP, HbA1c, HDL, BMI, DD,
and logMed in the past one year before time zero, as well as age, gender, and race variables. Finally,
we had data of (Ai,Zi, Ri) from 5,125 patients for learning optimal ITRs.
3.3.2 Learning ITRs Using Proposed Method
Figure 3.1 describes the flow-chart of our proposed framework, along with methods used at each
step. As illustrated in this figure, we used EHRs before time zero (last clinical encounter in year
2016) to fit joint models and learn subgroups for these patients. After using the 12-month-data
of HbA1c after time zero to define the outcome, we applied the multicategory matched learning
method in Section 3.2.2 to estimate optimal ITRs in each subgroup.
Figure 3.1: Flow-chart of learning optimal ITRs using the EHRs at the OSU-WMCIW.
Before estimating propensity scores, prognostic scores, and ITRs, we normalized all the continuous
variables to alleviate the bias introduced by scaling. Propensity scores, π(Zi), were estimated by
a 10-fold cross-validation random forest with 3 repeats. The misclassification rates on the whole
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training data were 3.1%, < 0.001%, 16.4%, 11.0% and 15.2% for each of groups 1 to 5, respectively.
The 5th and 95th percentiles of estimated propensities are around 0.01 and 0.80. To avoid extreme
weights in the calculation of value functions, we truncated probabilities less than 1% or greater than
80%. Similarly, prognostic scores, ψ(Zi), were estimated by a gradient boosting model with 5, 000
trees of which maximum depth was 4 in each patient subgroup. The model provided a good fit to
the clinical outcome with a mean squared error less than 10−4. The most important covariate in
estimating both propensity and prognostic scores is the recent one-year HbA1c.
Finally, in the doubly robust matching step in Section 3.2.2, we used the Euclidean metric as
the distance function d(·, ·) and the 1-nearest neighbor to create matched pairs. In other words,
for the ith patient, among other patients with the same gender and race but different baseline
treatments, we searched for the patient who has the closest Euclidean distance to him/her in terms
of demographics variables, recent measurements of health markers, and two estimated scores. We
applied the radial basis function (RBF) kernel to optimize the objective function (3.4) in the matched
learning model and 2-fold cross-validation with 100 repeats were used to learn optimal ITRs. The
tuning parameter was selected from
{
2k : k = 0,±1, . . . ,±15
}
using 2-fold cross-validation. We
calculated the bandwidth parameter of each RBF kernel according to a data-driven method which
could be implemented using the kernlab (Karatzoglou et al., 2004) R package.
Given ITRs, we used (3.5) in Section 3.2.2 to evaluate the optimal ITR and compare with the
universal rules of the four classes of treatments. In addition to the universal rules, we also compared
the model performance of our method with Q-learning. In Q-learning, we used all the feature
variables and the treatments in the model. Random forests and SVMs with RBF kernels were applied
to obtain parameter estimates through 2-fold cross-validation with 100 repeats via the caret (Kuhn,
2020) R package. The cost parameter in SVMs was also selected from
{
2k : k = 0,±1, . . . ,±15
}
using 2-fold cross-validation. The parameter that controls the number of features being randomly
selected at each node in random forests was chosen from a pool of 10 potential values which were
automatically determined by the caret package, using 2-fold cross-validation.
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3.4 Analysis Results of OSU-WMCIW EHRs
3.4.1 Identified Latent Subgroups
We identified 5 subgroups in the EHR datasets and patients in each cluster have similar health
profiles. Figure 3.2 shows the averages of normalized health marker measurements for patients
in each cluster. The value in each cell is averaged across all patients and clinical visits for the
corresponding health marker and patient subgroup. A higher value of HDL and a lower value of
HbA1c, HDL, and BMI indicate a healthier status. The value of DD and logMed do not directly
reflect the disease state. However, a lower value indicates that physicians tend to prescribe less
medications to this group of patients, and thus a less severe state. We compared these values to the
sample average of each health marker. A healthier T2D status is indicated in blue and a severe
condition is indicated in red.
Figure 3.2: Averages of normalized measurements by health markers and patient subgroups using
24-month-data before baseline treatment dates. Red: more severe status than the overall sample
average in terms of a health marker; Blue: healthier status than the overall sample average in terms
of a health marker; White: overall sample average status in terms of a health marker.
Group 5 is comprised of 1,231 patients. All the health markers convey the information that this
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group of people is relative healthier. Compared to other groups, patients in this group did not take
excessive number of medications. Group 2 contains 3,360 patients whose HDL is slightly lower than
the average. This suggests that they might have some difficulties in controlling the cholesterol level.
However, other health markers reflect a relatively healthy status of patients in this group. The SBP
of 737 patients in group 1 is apparently higher than the average, while other health markers are
below or around the averages. This pattern indicate that these patients might have hypertension
and a moderate status of T2D. Group 3 have 2,446 patients and their BMIs are above the average.
Besides BMI, the value of HDL in this group represent a bad signal as well. Thus, patients in
group were at a moderately severe state. For the 682 patients in group 4, almost all the health
markers show the most severe severe state of T2D. In particular, their HbA1c level is much higher.
Another interesting fact is physicians had prescribed more-than-average diabetic drugs and ancillary
medications to this group of patients, but their diseases were not controlled well. This result implies
that this group might not have received the optimal treatments, and, therefore, we would focus on
this group in the following analysis.
3.4.2 ITRs for Multicategory Treatments
As described in Section 3.3.1, we used 5,125 patients out of 8,456 patients in the finalized dataset
for learning optimal ITRs. Before estimating optimal ITRs on the whole dataset, we compared
the performance of the proposed method with the universal rules of four treatment classes and
Q-learning. The results of 100 cross-validation repetitions are displayed in Figure 3.3, and the
summary statistics are listed in Table B.1.
In general, the empirical HbA1c value of estimated ITRs is lower than any universal rules (i.e.,
“one-size-fits-all" rules) in any of the 100 repetitions. Compared to Q-learning using random forests
and SVMs, the proposed method has lower average empirical values in the majority of cases as well.
For example, in group 4, the weighted mean outcomes in (3.5) are 8.479, 9.199, 8.866, and 9.121
for patients prescribed metformin only, insulin only, other T2D drugs, and multiple treatments,
respectively. ITRs estimated by the proposed approach achieve a mean empirical value function of
7.752, which is lower than that for Q-learning using random forests (9.052) and Q-learning using
SVMs with RBF kernels (7.794). Furthermore, the standard deviations of our ITRs are relatively
small across all patient subgroups. Thus, we conclude the proposed M-learning model outperforms
universal rules and Q-learning on estimating ITRs for HbA1c control with a higher value and a
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Figure 3.3: The empirical value function for the expected HbA1c level using 2-fold cross-validation
with 100 repeats (a lower value means more beneficial).
lower variance.
After evaluating the model performance, we estimated the ITRs using the whole dataset. The
distributions of four treatment classes in baseline assignments and ITRs are displayed in Figure 3.4.
Taking group 4 as an example, there are 53 (14.2%) patients who received metformin only; 152
(40.8%) patients received insulin only; 88 (23.6%) received other T2D drugs; and 80 (21.4%) received
at least two treatments. However, in other patient subgroups, 25% to 35% of patients were assigned
metformin monotherapy, insulin monotherapy, and other T2D drugs, respectively. The proportion
of multiple treatments is around 8% to 15%. Thus, the proportion of patients in group 4 receiving
metformin monotherapy is much lower than that in other groups, while the normalized HbA1c level
of group 4, as shown in Figure 3.2, is the highest among all groups.
Compared to the observed baseline treatments, the proportion of assigning either metformin
monotherapy or other T2D drugs increases in almost every patient group. In contrast, the estimated
ITRs suggest to prescribe insulin to less patients than observed. The proportions of metformin
monotherapy and other T2D drugs recommended by the ITRs are fairly close; however, in group 4,
metformin has a drastic increment in the assignment proportion from 14.2% to 40.2%. Similarly,
in group 5, the proportion of insulin monotherapy decreases from 38.1% to 20.4%, together with
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Figure 3.4: The distribution of observed treatments vs treatments recommended by estimated ITRs
within each subgroup.
observable increases in the assignment of metformin monotherapy and other T2D drugs.
Table 3.1 displays the contingency table of observed treatments and the estimated ITRs recom-
mendations. For metformin monotherapy, observed treatments and ITRs are matched by about
50% to 60% times. The proportion of other T2D drugs ranges from 40% to 60% across patient
groups. Nevertheless, the observed insulin monotherapy merely has about a 30% to 40% match
rate with ITRs. Particularly, in group 3, 4 and 5 of which patients have the highest HbA1c
measurements, ITRs tend to assign metformin and other T2D drugs to more than 65% of patients
who originally received insulin. We also investigated the agreement of the observed prescriptions
and estimated ITRs using the Cohen’s kappa coefficient κ (Cohen, 1960). As shown in Table 3.2,
all of the κ coefficients for the 4× 4 contingency tables of group 1 to 5 (rows “overall”) are between
0.179 and 0.247. McHugh (2012) suggested any κ value below 0.4 indicates at least moderate
disagreement between the two categorical variables. Therefore, this result reveals the moderate
disagreement between the observed prescriptions and estimated ITRs in all the identified patient
subgroups. Moreover, we decomposed the “overall” disagreement to individual treatment class level
by comparing each of the four treatment classes versus the rest. The κ values for all comparisons
are less than 0.4, suggesting the consistent disagreement of all treatment classes. Particularly, for
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Table 3.1: Contingency tables of four treatment classes by observed prescriptions (rows) and
estimated ITRs (columns).
Group Other Insulin Metformin Multiple Total in
drugs only only drugs prescriptions
Group 1 Other drugs 42 41 5 12 100
Insulin only 43 55 38 9 145
Metformin only 21 38 68 4 131
Multiple drugs 11 28 15 15 69
Total in ITRs 117 162 126 40 445
Group 2 Other drugs 242 200 55 40 557
Insulin only 160 199 124 27 510
Metformin only 319 17 342 7 685
Multiple drugs 44 44 109 40 237
Total in ITRs 765 480 630 114 1989
Group 3 Other drugs 168 82 116 19 385
Insulin only 183 152 95 13 443
Metformin only 69 127 237 14 447
Multiple drugs 71 46 40 46 203
Total in ITRs 491 407 488 92 1478
Group 4 Other drugs 52 20 10 6 88
Insulin only 13 50 87 2 152
Metformin only 20 2 28 3 53
Multiple drugs 23 5 25 27 80
Total in ITRs 108 77 150 38 373
Group 5 Other drugs 93 30 38 34 195
Insulin only 115 94 88 23 320
Metformin only 37 36 156 25 254
Multiple drugs 17 11 25 18 71
Total in ITRs 262 171 307 100 840
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Table 3.2: Cohen’s kappa coefficients for the agreement of observed prescriptions and estimated
ITRs.
Group Treatment Value SE Z P-value
Group 1 Overall 0.179 0.032 5.576 <0.001
Other drugs 0.191 0.051 3.757 <0.001
Insulin only 0.022 0.047 0.463 0.643
Metformin only 0.338 0.048 6.973 <0.001
Multiple drugs 0.182 0.060 3.052 0.002
Group 2 Overall 0.180 0.015 11.877 <0.001
Other drugs 0.062 0.022 2.818 0.005
Insulin only 0.204 0.024 8.477 <0.001
Metformin only 0.284 0.022 12.622 <0.001
Multiple drugs 0.163 0.031 5.318 <0.001
Group 3 Overall 0.181 0.018 10.314 <0.001
Other drugs 0.129 0.026 4.886 <0.001
Insulin only 0.099 0.027 3.696 <0.001
Metformin only 0.280 0.026 10.610 <0.001
Multiple drugs 0.247 0.036 6.872 <0.001
Group 4 Overall 0.247 0.031 7.851 <0.001
Other drugs 0.366 0.053 6.839 <0.001
Insulin only 0.224 0.047 4.744 <0.001
Metformin only 0.083 0.042 1.957 0.050
Multiple drugs 0.371 0.060 6.163 <0.001
Group 5 Overall 0.218 0.022 9.835 <0.001
Other drugs 0.192 0.036 5.396 <0.001
Insulin only 0.160 0.033 4.917 <0.001
Metformin only 0.337 0.034 9.970 <0.001
Multiple drugs 0.124 0.044 2.794 0.005
Note: In column “Treatment”, for each group, “Overall” represents the 4× 4 contingency table in
Table 3.1. The other four labels represent the 2× 2 contingency tables for each of the four treatment
classes versus the rest, respectively; “Value” is the value of Cohen’s kappa coefficient κ for the
corresponding contingency table; “SE” is the asymptotic standard error of κ; “Z” is the test statistic
for a z-test with the null hypothesis κ = 0; “P-value” is the p-value for the z-test.
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the assignments of insulin monotherapy in group 1 and metformin monotherapy in group 4, the κ
coefficients are not significantly different from 0 (p-values are 0.643 and 0.050, respectively), so we
could not reject the null hypothesis that the agreement is the same as chance agreement in these
two cases.
Bringing all the comparisons together, we can conclude that metformin monotherapy has the
optimal effect on HbA1c control, i.e., with the smallest HbA1c level at 6 months, especially for
patients with low or moderate HbA1c levels. Whereas, the insulin monotherapy does not have
noticeable advantages over other T2D drugs, and may even have worse HbA1c management when
the baseline HbA1c level is high. Also, the insulin monotherapy may not be optimal to people
who are relatively healthy and do not suffer from T2D complications. In this case, physicians may
consider to prescribe either metformin monotherapy or other T2D drugs. These conclusions agree
with the findings in Palmer et al. (2016) and may provide new directions to test treatment effects of
T2D drugs.
3.4.3 Interpretable ITRs
To improve the interpretability of optimal ITRs, we employed the SHAP value approach
(Lundberg and Lee, 2017) to examine the importance of features by each patient group. For each
of the six binary classifiers in the weighted SVM in the M-learning model, we used the fastshap
(Greenwell, 2020) R package to compute the approximate Shapley values using 10 Monte Carlo
simulations for each row in the dataset and each feature. Taking the absolute value of all Shapley
values, we computed the average across all incidences for each value, and treated these averages as
the importance of features. The results are presented in Figure 3.5.
The most informative features in estimating ITRs are the prognostic scores and three propensity
scores. The propensity scores summarize the observed treatment patterns that patients received.
This result suggests that incorporating the propensity and prognostic scores is crucial to not only
the doubly robust matching estimator framework but also the determination of ITRs. Gender and
race have less important effects on optimal treatments, while age and the remaining six features
related to health markers have moderate and non-negligible impacts on the estimated ITRs.
3.5 Discussion
In this chapter, we propose a general framework to estimate optimal ITRs for multicategory
treatments using EHRs. Our first contribution is to create a novel latent process model, which
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Figure 3.5: Importances for feature variables based on the absolute values of Shapley values. Prog:
prognostic score. PropI: propensity score for insulin monotherapy. PropO: propensity score for
other T2D drugs. PropM: propensity score for metformin monotherapy.
jointly analyzes different types of health markers and accounts for informative measurement patterns.
Using patient similarities estimated from the latent process model, we identify subgroups of patients
with homogeneous health profiles. The identified patient subgroups show different health patterns,
and the cluster membership of patients is an important feature in M-learning to match patients
among a more homogeneous pool.
The second contribution is the generalization of M-learning to multicategory treatments. We
reduce the problem of selecting the optimal option among multicategory treatments into multiple
binary classification problems using the one-versus-one strategy, and use the majority voting to
integrate the results of the binary classification problems. Using this doubly robust multicategory
M-learning, which incorporates propensity scores and prognostic scores, we reduce the confounding
due to both covariates and recent patterns of health markers. Thus, our approach tackles the
challenges in EHRs, and takes full advantage of information available from the health markers.
Compared to any universal rules, our ITRs lead to a better control of the HbA1c level up to 13%.
This result suggests our method is practical, and assists in the prescription of T2D treatments for
HbA1c management.
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We proposed a general pipeline (Figure 3.1) to learn the optimal treatment rules using the EHR
data. However, there are certainly alternative ways to use in each component of this pipeline. For
example, instead of using the hierarchical clustering, other clustering methods such as k-means
(Forgy, 1965) or Gaussian mixture models may be used to identify the latent patterns in the EHRs.
Also, the optimal number of patient subgroups may be selected by objective statistics (Rousseeuw,
1987; Tibshirani et al., 2002) using automated algorithms (Kassambara and Mundt, 2020). Another
potential extension is that the outcome, HbA1c level at 6 months, was interpolated based on a
linear function using one-year data since the HbA1c value changes slowly and smoothly. However,
more sophisticated interpolation models such as splines may be useful if the measurements are taken
intensively or over multiple years. In our application, there is a significant difference in the patients
that are recommended metformin monotherapy between the observed prescriptions and estimated
ITRs, especially for the patient group with the highest baseline HbA1c level. One possible reason
for the discrepancy is we merely focus on glycaemic control, while, in real world, clinicians have
to concern about other clinical outcomes or dose-related adverse events such as hypoglycaemia,
gastrointestinal disorders, and renal failure. Thus, we can extend our work by considering the
balance control of clinical outcomes and adverse events. Finally, our proposed framework focuses on
finding the optimal treatment in a short period of time at a single decision point (e.g., at a patient
visit). The method is not designed to optimize the long-term outcome over years and after multiple
treatment phases. To adjust for the delayed effect in sequential decision making or long-term health
management, our methods can be extended to learn the optimal dynamic treatment regimes to
maximize the long term reward.
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CHAPTER 4: IDENTIFICATION OF OBJECTIVE BIOMARKERS FOR
ADVERSE POSTTRAUMATIC NEUROPSYCHIATRIC SEQUELAE USING
MOBILE SENSOR DATA
4.1 Introduction
Adverse posttraumatic neuropsychiatric sequelae (APNS) are common among trauma survivors
after experiencing traumatic events such as car crash, physical and sexual assault, and natural
disasters (Kessler, 2000). Common APNS disorders include posttraumatic stress disorder (PTSD),
depression, post-concussion syndrome, and regional or widespread pain (McLean et al., 2020).
Similar to many other mental health disorders, APNS classification and diagnosis are mainly
based on subjective self-report measures that are not well mapped to underlying neurobiological
mechanisms. Consequently, patients diagnosed with the same APNS disorder often experience very
heterogeneous symptoms. Another issue of the self-report measures stems from the fact that more
than half of people with any mental illness do not receive treatments or avoid treatments (Mental
Health America, 2020). Even people who seek help often have a delay between the occurrence of
the illness and clinical visits. In this case, the self-report measures, laboratory tests, and clinical
diagnoses at a single point of time are probably inaccurate due to the delay. As a result, lack of
objective measures has greatly impacted the research for APNS disorders, and the identification of
objective biomarkers is critical to advancing APNS and mental health research.
Jain et al. (2015) firstly attempted to define the concept of digital phenotyping and described
the opportunities in incorporating mobile sensor data into healthcare. They argued that if a person
suffered from any disease, the mobile sensors they wear could trace the disease expressions, so the
patterns in digital data could reflect disease symptoms. Later, Insel (2018) discussed the future
of digital phenotyping and its potential functions in psychiatry and mental health. He stated
the primary merit of digital phenotyping was that the digital phenotyping continuously recorded
the objective signals of a person in their daily life, which could be different from the information
they reported to clinicians later. Thus, besides the traditional clinical data, additional sources of
continuous measurements can provide psychiatrists new insights into the assessment, treatment,
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and prevention of mental illnesses. On the other hand, the development in sensor technology
and information science makes digital data become an objective and ecological source of such
measurements. In the past decade, a large variety of portable and interconnected mobile devices,
such as smartphones, smartwatches, and wristband activity trackers, have been developed and
widely used in daily activities by individuals of all ages and ethnicities around the world (Reinertsen
and Clifford, 2018). Various types of sensors are built into these mobile devices, and massive amount
of objective psychophysical signals are collected continuously by passive sensing from mobile device
users over time. For example, smartphones have seven physical sensors which monitor the physical
activity, sleep, and heart rate signals of users (Cornet and Holden, 2018).
Mobile sensor data provide invaluable information about the daily behaviors of users and have
attracted an increasing attention from researchers in the field of mental health since 2010. For
instance, Moshe et al. (2021) recruited 60 adult participants to explore the use of daily-life behaviour
markers in the prediction of symptoms of depression and anxiety, using smartphones and wearable
devices. Participants were continuously monitored over a 2-week period during which measures
related to GPS, phone usage, activity, sleep, and HRV were recorded. The findings based on these
data demonstrated a number of features had significant correlations with symptoms of depression
and anxiety. Furthermore, smartphone features, wearable device features, and patient self-reported
mood scores together provided the strongest prediction of depression. Depp et al. (2019) conducted
a research to check the association between GPS data and symptom clusters in schizophrenia. Depp
and colleagues collected GPS locations, which were tracked every 5 minutes by smartphones, and
ecological momentary assessment reports of locations and behaviors from a total of 142 participants
with schizophrenia (n=86) or healthy comparison subjects (n=56). They found the less GPS mobility
was related to negative symptoms of schizophrenia. Thus, they concluded passive GPS sensing could
be used for interventions for schizophrenia. Haines-Delmont et al. (2020) recently published an
implementation of digital phenotyping in the suicide risk prediction. 66 qualified patients consented
to participate the experiment, and their health information such as sleep behavior, mobility, and
phone usage were collected up to a week through a smartphone application (“app”), which was linked
to commercial wristbands and social networks. As a result, the research team proposed an algorithm
that revealed the potential for discriminant suicide risk predictions, utilizing smartphone-generated
and passive sensing data. Other representative research using mobile sensor data, classified by
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mental illnesses, can be found in the fields of bipolar disorder (Faurholt-Jepsen et al., 2015; Abdullah
et al., 2016; Beiwinkel et al., 2016; Palmius et al., 2017; Faurholt-Jepsen et al., 2019), schizophrenia
(Wang et al., 2016; Staples et al., 2017; Barnett et al., 2018), depression (Saeb et al., 2015; Canzian
and Musolesi, 2015; Ben-Zeev et al., 2015; Jacobson et al., 2019), PTSD (Karstoft et al., 2015;
Minassian et al., 2015; Pyne et al., 2016; Place et al., 2017; Bourla et al., 2018), suicidal thoughts
(Husky et al., 2014; Hallensleben et al., 2017; Kleiman et al., 2017, 2018), and stress (Muaremi et al.,
2013; Sano and Picard, 2013; Sano et al., 2018; Goodday and Friend, 2019; DaSilva et al., 2019).
However, Linnstaedt et al. (2020) pointed out that there had been few progresses on the
classification and ontology of APNS, and this was partially due to the lack of large-scale longitudinal
studies that tracked APNS in large populations to achieve a sufficient statistical power and replicable
findings. To help address these challenges, the National Institutes of Mental Health, collaborating
with the US Army Medical Research and Material Command and several foundations, institutions,
and companies, developed the AURORA study (McLean et al., 2020). The AURORA study is
an ongoing large-scale (n=5000 target sample) cohort study that enrolls trauma survivors at the
emergency department and follows them for one year. During the 1-year period, self-report indicator
variables, genomic, neuroimaging, psychophysical, physiological, neurocognitive, and mobile sensor
data are collected. These multi-layered longitudinal data from the AURORA study provide the field
with unparalleled opportunities to advance the research on the classification and ontology of APNS.
According to McLean et al. (2020), one of the primary goals of the AURORA study was to develop
clinical decision tools for multidimensional APNS outcomes using the range of biobehavioral data
collected. Motivated by this, we aimed to build a framework to predict construct scores, which were
based on self-report indicator variables, and identify objective biomarkers related to APNS.
Although mobile sensor data provide great opportunities to advance mental health research, they
also bring some unique analytical challenges. First of all, mobile sensor data are often in the form
of high-frequency high-dimensional time series data. For example, the heart rate measurements
traditionally are monitored every minute, so the number of features is 1440 for each day without
any feature engineering. Additionally, mobile sensor data can be highly correlated. For instance,
the heart rate measurements of different days have cyclic patterns for the same person. Finally,
multimodal sensing may cause different time scales in mobile sensor data across domains. Again,
heart rate measurements are monitored every minute, while measurements of sleep quality are
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collected daily or every 12 hours. As a result, the features with finer resolutions will overwhelm
others. These challenges make the modeling techniques for mobile sensor data be different from
those for the data used by clinicians, which are subjective, infrequently sampled, and small-scale
(Reinertsen and Clifford, 2018).
To overcome aforementioned data challenges, existing literature in mobile sensor data applications
have adopted various data-mining techniques to solve formulated supervised learning tasks as ours.
Among these literature, the most commonly used analytical methods are support vector network
models (Ferdous et al., 2015; Abdullah et al., 2016; Wahle et al., 2016; Kelly et al., 2017; Sano et al.,
2018), decision tree based models (Stütz et al., 2015; Garcia-Ceja et al., 2016; Jacobson et al., 2019;
Faurholt-Jepsen et al., 2019), and variations of linear models (Saeb et al., 2015; Place et al., 2017;
DaSilva et al., 2019; Moshe et al., 2021). Support vector network models consist of SVMs and SVRs,
and they have been proved to be powerful methods for handling high dimensional data and solving
classification/regression problems. Common passive sensing features considered by support vector
network models are extracted from ECG and photoplethysmography (PPG). However, support
vector network models require careful data preprocessing and parameter tuning. Furthermore, an
increase in the sample size or the number of features can drastically increase the computing source
of running support vector network models. Lastly, it can be difficult to explain the support vector
network models to non-statisticians and identify the informative biomarkers if the linear kernel is
not chosen. Decision tree based models, including random forests and gradient boosting methods,
have been employed for handling classification/regression tasks on a mixture of categorical and
continuous features. Thus, they are suitable for data collected from multiple digital sensors across
domains. Additionally, compared to support vector network models, decision tree models are simpler
and easier to interpret. Nevertheless, the performance of decision tree models can be limited under
the case of overwhelming noise features. Therefore, decision tree models are not usually applied
to high-frequent and/or high-dimensional sparse data. Linear models have been well studied and
they can serve as the baseline models for most tasks. The generalized forms of linear models enable
them to handle different types of outcomes. It is fast to train a linear model and make predictions.
Also, it is easy to understand and explain the prediction results of linear models. Moreover, in
high-dimensional spaces, linear models often have a powerful performance. The use of regularization
parameters (L1, L2, elastic net) gives linear models the capability of performing feature selection.
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In particular, LASSO (Tibshirani, 1996) is appropriate for using when the interpretability of the
model is given the greatest consideration. The primary downside of linear models is the complexity
of specifying interaction terms between features. Hence, the nonlinear relationship between the
outcome and features can hardly be captured, and the predictions probably are biased.
Accounting for the challenges of using mobile sensor data and the findings in existing literature,
it is unreasonable to simply input raw features from all types of mobile sensors into any single
model or just use the features filtered by marginal screening methods (Lo et al., 2015). Instead,
we propose a two-stage model to predict the continuous construct scores and identify objective
biomarkers. In the first stage, we use a linear regression model with LASSO penalties to perform
variable selection so that we improve the model interpretability. Specifically, in the linear model, we
assign weights to features measured on different days and in different hours, and then we penalize
the objective function for these weights and estimate the weights. Purposes of the first stage are to
reduce the dimension of feature sets and select those features carrying the majority of the model
effect. Also, the use of weights unifies the heterogeneous time scales of different domains of features,
while keeping the most representative time-lag signals as much as possible. However, it is possible
that the linear structure between construct scores and features is misspecified. Hence, to capture
the nonlinear interactions between different domains of features, we apply a SVR model in the
second stage. In this step, we plug the weights estimated from the first stage into a customized
kernel function to further reduce the heterogeneity of different scales. Using the two-stage model,
we not only select the most informative features but also combine the effects of various resolutions
and temporal patterns. Therefore, we strike a balance between the prediction accuracy and model
explainability.
The remaining part of this chapter are organized as follows. In Section 4.2, we introduce the
data source of this chapter. In specific, we explain, in the AURORA study, the procedures of
collecting raw data from mobile sensors, creating constructed scores, and selecting mobile sensor
feature sets. In Section 4.3, we define the proposed model and describe our step-by-step algorithm
for estimating model parameters. In Section 4.4, we illustrate an implementation of our method
to a mobile sensor dataset collected by the AURORA study. We explore the relationship between
three sets of features – demographic, activity, HRV features – and construct scores related to the
pain experience of participants. Finally, we compare the performance of our method with three
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alternative models and report the result.
4.2 Materials
4.2.1 Data Collection
The AURORA study has collected a large amount of digital sensing data, including HRV, activity,
and sleep data from Verily’s smartwatches, as well as keystroke, GPS, text, and voice data from the
Mindstrong Discovery™ app on smartphones. The current research focuses on the identification of
objective biomarker of APNS based on HRV data and activity data collected from smartwatches.
The unprocessed HRV data and constructed HRV features were derived based on PPG signals on
5-minute sliding windows, which overlapped continuously for four and a half minutes. Meanwhile,
the raw data and features of physical activities were obtained daily from accelerometer signals.
In this chapter, we used the Research Domain Criteria (RDoC) framework (National Institute of
Mental Health, 2021) to classify APNS, and we defined 10 RDoC related constructs - pain, loss, sleep
discontinuity, nightmare, anxiety, hyperarousal, avoidance, re-experience, somatic and mental fatigue
- by self-report indicator variables of participants. Self-report indicator variables were selected by
domain experts from a rotating battery of smartphone-based survey. Each survey was administered
at 6 different time points within the first 8 weeks after the traumatic event of each participant.
To create factor scores for the 10 constructs, a joint measurement model (factor analysis model)
across all 6 time points were developed for each construct, and then the performances of model fit
were evaluated by different indices such as the comparative fit index (Bentler, 1990), standardized
root mean square residual (Hooper et al., 2008), and Tucker-Lewis index (Tucker and Lewis, 1973).
Finally, construct (factor) scores at all 6 time points were calculated for each construct using the
joint measurement model.
4.2.2 Construct Scores
Preliminary results of the AURORA study revealed, among the 10 RDoC constructs, pain
had a relatively strong association with the collected mobile sensor data, especially those from
smartwatches. Thus, for this chapter, we selected the construct scores of pain as the outcome
variables. The scale of the self-report indicator variable for pain ranged from 0 to 10, representing
no pain to severe pain. The details of self-report indicator variable for pain in smartphone-based
follow-up surveys can be found in Table 4.1.
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a. How would you rate your pain in the past 24 hours at its
worst?
b. How would you rate your pain in the past 24 hours on
average?
4.2.3 Feature Sets
To predict the outcome scores, we used two fields of feature variables collected from mobile
sensors: activity features and HRV features. 8 activity features in Table 4.2 were extracted from
the preprocessed accelerometer signals, and these features were extracted daily. In particular, the
activity feature set consisted of descriptive statistics of activity counts, cosinor-based rhythmometry
(Cornelissen, 2014) metrics, and movement measurements. The mean of activity counts (meanACC)
and standard deviation of activity counts (stdACC) were calculated for each 24-hour epoch of the
accelerometer data, and they belonged to descriptive statistics of activity counts. After fitting
a cosine model to the accelerometer data, the acrophase of cosinor rhythmometry (Acrophase)
and amplitude of cosinor rhythmometry (Amplitude) were estimated. Acrophase represented the
difference between the time point when daytime/nighttime switched and the starting time point
of the 24-hour epoch. Amplitude indicated the difference between activity counts during daytime
and nighttime. Finally, movement measurements included the wake percentage (wakePercentage),
sleep-wake fragmentation (SWfragmentation), least active five hours (L5), and relative amplitude
(RA). wakePercentage and SWfragmentation revealed the restfulness or restlessness due to sleep
disturbances, while L5 and RA quantified the average activity in the waking and sleeping periods.
11 HRV features in Table 4.3 were derived from PPG signals, and these features were computed
over 5-minute time windows and updated every 30 seconds. Specifically, the HRV feature set
consisted of time-domain measures, frequency-domain measures, and non-linear measures (Shaffer
and Ginsberg, 2017). Most HRV time-domain measurements were related to the descriptive
statistics of interbeat intervals from which artifacts have been removed (NN intervals) and intervals
between all successive heartbeats (RR intervals). For instance, we used the mean of NN Intervals
(NNmean), interquartile range of NN Intervals (NNiqr), skewness of NN Intervals (NNskew),
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Table 4.2: Activity feature set
Feature Name Description
meanACC Mean of actigraphy in a 24-hour time window.
stdACC Standard deviation of actigraphy in a 24-hour time window.
Acrophase* Parameter in the cosine model which fits to actigraphy data.
Amplitude* Parameter in the cosine model which fits to actigraphy data.
wakePercentage** Number of waking epochs divided by data length.
SWfragmentation** Number of transitions between waking and sleeping epochs
divided by data length.
L5 Least active 5 hour period in an the average 24 hour pattern.
RA Normalized difference between the most active 10h period
and least active 5h period in an average 24h pattern.
*: The cosine model was fitted following Cornelissen (2014).
**: The waking and sleeping epochs were classified by the Cole-Kripke algorithm (Cole et al., 1992).
kurtosis of NN Intervals (NNkurt), average Signal-Quality-Index (avgsqi), standard deviation of NN
Intervals (SDNN), root-mean square differences of successive RR intervals (RMSSD), and heart rate
deceleration capacity (dc) as time-domain measurements. These features quantified the short-term
variability of heartbeats. Meanwhile, using the Fast Fourier Transformation or autoregressive model,
the variability of heart rates were separated into different rhythms that operated in ultra-low-
frequency, very-low-frequency, low-frequency, and high-frequency bands (Task Force Report, 1996).
Consequently, frequency-domain measures were created to estimate the distribution of signal energy
in these four frequency bands. We included one such measurement into our model, and it was the
ratio of low and high frequency spectral contents (LF/HF). Lastly, two non-linear measures - the
ratio of two standard deviation measures for a Poincare plot (SD1/SD2) and approximate entropy
(ApEn) - helped us evaluate the unpredictability, regularity, and complexity of RR time series.
Figures 4.1 and 4.2 display the scatter plots and correlations of the activity and HRV feature
variables of 1000 randomly selected entries. Most of the feature variables have weak or moderate
correlations between each other, but none of the absolute values of the correlations exceeds 0.85.
4.3 Methods and Algorithms
In this section, we build a regression model to predict the construct scores, using HRV and
activity data collected before/on each of the 6 time points. By looking for informative features in
the finalized model, we could identify the objective biomarkers for APNS related constructs. Figure
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Table 4.3: HRV feature set
Feature Name Description
NNmean Mean of NN intervals calculated in five-minute windows.
NNiqr Interquartile range of NN intervals calculated in five-minute
windows.
NNskew Skewness of NN intervals calculated in five-minute windows.
NNkurt Kurtosis of NN intervals calculated in five-minute windows.
avgsqi Average Signal-Quality-Index in five-minute windows.
SDNN Standard deviation of NN intervals calculated in five-minute
windows.
RMSSD Root-mean square differences of successive RR intervals.
LF/HF Ratio of frequency activities in the low frequency (0.04 -
0.15Hz) range to the high frequency (0.15 - 0.40Hz) range.
dc Average capacity of an autonomic nervous system to decel-
erate heartbeats (Jänig, 1989).
SD1/SD2 The ratio of SD1 to SD2 (Tulppo et al., 1996).
ApEn Entropic measurement to quantify the regularity of medical
data (Pincus et al., 1991).
Note: for each feature, we calculated four hourly summary statistics (mean, max, min, standard
deviation). We used labels such as NNmeanmean, NNmeanmax, NNmeanmin, and NNmeanstd to
denote these metrics.
Figure 4.1: Scatter plots and correlations of activity feature variables.
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Figure 4.2: Scatter plots and correlations of HRV feature variables.
4.3 describes the flow-chart of our proposed framework and the method used at each step.
4.3.1 Penalized Least Squares Estimation
Suppose there are N subjects in the mobile sensor dataset, and the finest time points for
outcomes are T1, T2, . . . , Tn. Let Yt = (Y1t, . . . , YNt)T be the outcome for all subjects at time t,
and Xt = (Xt1, . . . ,Xtp)T , where Xtj contains sj feature variables from the jth domains at time t.
In this specific example, Yt is the vector of construct scores of pain (see Section 4.2.2), and Xtj
represents the activity features and HRV features as described in Section 4.2.3.
To quantify the relationship between outcome Yt and feature Xtj , we propose the following
working model: for the ith subject,







itjlβj + εit, (4.1)
where Zi is the vector of baseline covariates, which are set to demographic variables in this example.
εit ∼ N (0, σ2t ), i = 1, . . . , N , are i.i.d. random errors. ωjl indicates the time-lag weight for the jth
domain at l days before time t. X̃itjl is the vector of feature variables measured l days before time
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Data resource Methods/Models Details/Explanations
Calculate HRV hourly summary statistics 
𝑋𝑋𝐻𝐻𝐻𝐻𝐻𝐻
Create HRV daily features �𝑋𝑋𝐻𝐻𝐻𝐻𝐻𝐻
For each day, if all 𝑋𝑋𝐻𝐻𝐻𝐻𝐻𝐻𝑏𝑏 of the first 6 hours are non-missing, let 
�𝑋𝑋𝐻𝐻𝐻𝐻𝐻𝐻 = ∑𝜆𝜆𝑏𝑏𝑋𝑋𝐻𝐻𝐻𝐻𝐻𝐻𝑏𝑏 . Time scale weights 𝜆𝜆𝑏𝑏 ≥ 0 and ∑𝜆𝜆𝑏𝑏 = 1.
For each hour, if there are more than 20 HRV 5-min-window 
data, calculate hourly mean/std/min/max.  
HRV 5-min-window data, 
measured every 30 seconds
Assume 𝑌𝑌 = 𝛾𝛾𝑇𝑇𝑍𝑍 + ∑𝑗𝑗∑𝑘𝑘𝜔𝜔𝑗𝑗𝑘𝑘𝛽𝛽𝑗𝑗𝑇𝑇 �𝑋𝑋𝑗𝑗𝑘𝑘 + 𝜖𝜖, and 
estimate 𝛾𝛾, 𝜔𝜔, 𝛽𝛽, 𝜆𝜆
Use the selected features to train SVM 
Time lag weights 𝜔𝜔𝑗𝑗𝑘𝑘 ≥ 0 and ∑𝑘𝑘𝜔𝜔𝑗𝑗𝑘𝑘 = 1. Apply lasso penalty 
to 𝛽𝛽 and fused lasso to 𝜔𝜔.
ACT daily features, �𝑋𝑋𝐴𝐴𝐴𝐴𝑇𝑇
Demographics, 𝑍𝑍
Pain scores, 𝑌𝑌
Determine sample size, and split data to 
training (80%) and test sets (20%).
𝑗𝑗 = 𝐻𝐻𝐻𝐻𝐻𝐻,𝐴𝐴𝐴𝐴𝐴𝐴. 𝑘𝑘 = 1,2. For 2 consecutive days prior to an 
observed pain score 𝑌𝑌, if �𝑋𝑋𝑗𝑗𝑘𝑘 are non-missing, include this 𝑌𝑌
into the sample. Denote the dimension of �𝑋𝑋𝑗𝑗⋅ to 𝑠𝑠𝑗𝑗.
Feature selection Exclude features (demographics, ACT, HRV) with regression coefficients |𝛽𝛽| < 0.01.
Exploit a custom kernel on two samples 𝐻𝐻 and 𝐻𝐻′,
𝐾𝐾 𝐻𝐻,𝐻𝐻′ = exp −
1
2𝜎𝜎2 𝑍𝑍 − 𝑍𝑍𝑍
2 + �
𝑗𝑗
∑𝑘𝑘 �𝜔𝜔𝑗𝑗𝑘𝑘 �𝑋𝑋𝑗𝑗𝑘𝑘 − �𝑋𝑋𝑗𝑗𝑘𝑘′
2
𝑠𝑠𝑗𝑗
Use 5-fold cross-validations to tune hyperparameters.Predict pain scores, �𝑌𝑌, on test sets
Repeat the above procedures for 10 times 
and take average results. Compare the 
results with sophisticated ML methods









Figure 4.3: Flow-chart of predicting construct scores of pain using mobile sensor data in the
AURORA study.
t. Here, X̃itjl = Xitjl if feature variables from the jth domain are measured on the same time scale
as the outcomes. Otherwise, if the measurement time scale of feature variables are finer, X̃itjl is an





where Xitjlb is the value of Xitjl at grid b, and mj is the ratio of the time unit of outcome
measurements to the time unit of feature measurements.
We assume kj , γ, βj , ωj , and λj are unknown and need to be estimated. kj = 1, . . . ,Kj (that
is, for daily outcomes, retrieve the feature variables of previous Kj days at most). γ is a vector
of length m + 1. βj is a vector of length sj . ωj is a vector of length kj . λj is a vector of length
mj . To estimate these parameters, we apply the following penalized least squares method with the






















































The detailed algorithm for estimating the parameters in (4.3) is described in Algorithm 1.
The proposed model has important advantages on handling the challenges of mobile sensor
data. Firstly, for each of the 6 time points at which surveys from participants were collected, we
estimate the relationship between construct scores and temporal features. Thus, it is unnecessary to
assume the construct scores of the same subject were identically distributed. Instead, the proposed
model takes into account the potential heterogeneities of instances due to the change in time
points. Additionally, we use the time-scale weights λj to rescale the effects of different domains of
temporal features on construct scores, so the effects become comparable and the bias introduced
by different domains can be alleviated. Moreover, we use the time-lag weights ωj to account for
the auto-correlation among temporal features observed at nearby time stamps and quantify the
lagged effects of temporal features on the construct scores. Another advantage of the proposed
method is that the use of the LASSO penalty on βj can select the most informative features and
overcome the curse of dimensionality. For example, βj = 0 implies the features in the jth domain
do not have observable effects on the outcome. Thus, the model has the function of group-typed
feature selection. Lastly, the use of fused LASSO penalty on ωj guarantees the smoothness in lagged
observations of temporal features.
4.3.2 Prediction through SVR with Customized Kernel
The parameter estimation in Section 4.3.1 assigns weights to each modality but does not consider
between-modality interactions. Thus, we next use kernel machines and apply the SVR to incorporate
potential nonlinear interactions and improve predictions. In this method, the key step is to define






. For our purpose,
we employ the time-lag weights to define the kernel distance
K(Hiti ,Hi′ti′ ) = exp
− 12σ2








∥∥∥X̃i,ti,jl − X̃i′,ti′ ,jl∥∥∥2
 , (4.4)
where ω̂jl are the estimators of time-lag weights obtained from (4.3). In (4.4), we firstly compute the
lagged differences between rescaled temporal features, which are on the same scale across domains,
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Algorithm 1: Algorithm for estimating parameters in (4.3).
Result: Estimates of kj , γ, βj , ωj , and λj , j = 1, . . . , p.
Denote set K = {(k1, . . . , kp)} and set A = {(α1, α2)}.
for (α1, α2) ∈ A do
for (k1, . . . , kp) ∈ K do
1. Initialize θ. Fit a linear regression of Y on Z to obtain γ(0). Set ω(0)j = Ikj/kj ,
λ
(0)







. In this step, s = 0.
2. Update θ. while
∥∥∥θ(s+1) − θ(s)∥∥∥
2
< 10−4 or s ≤ 100 do
(a) Given β(s)j , ω
(s)
j , and λj , minimizing (4.3) w.r.t γ is equivalent to solving a
least square problem. Denote the estimates to γ(s+1).
(b) Given β(s)j , ω
(s)
j , and γ(s+1), minimizing (4.3) w.r.t λj is equivalent to solving
a least square problem under nonnegativity and linear constraints. Denote the
estimates to λ(s+1)j .
(c) Let δj1 = ωj1 and δjl = ωjl − ωj,l−1. Then
∑kj
l=1 ωjl = 1 yields∑kj
l=1
∑l
c=1 δjc = 1. Thus, δj1 = [1−
∑kj
l=2(kj + 1− l)δjl]/(kj + 1). Substitute
ωj1, . . . , ωjkj with δj2, . . . , δjkj in (4.3). Given β
(0)
j , γ(1), and λ
(1)
j , minimizing
(4.3) w.r.t δj is equivalent to solving a least square problem with LASSO
penalties and linear constraints. According to Gainesa et al. (2018), this
problem can be converted to a quadratic programming. Denote the estimates to
δ̂j , and then transform δ̂j to ω(s+1)j .
(d) Given γ(s+1), ω(s+1)j , and λ
(s+1)
j , minimizing (4.3) w.r.t βj is equivalent to





3. Denote the estimates at the end of step 2 to γ̂, β̂j , ω̂j , and λ̂j , j = 1, . . . , p.







(b) Estimate the variance of εt as the sample variance of Yit − Ŷit. Denote it to σ̂2t .





















t 1)− 2 ln(L)], where
P = 1 +m+
∑p
j=1(sj + kj +mj), the number of parameters estimated by the model.
Denote the optimal values to k̂j , j = 1, . . . , p.
end
Select the optimal α1 and α2 from A by cross-validation (for each fold of data, conduct step
1 to 4). The corresponding estimates of kj , γ, βj , ωj , and λj , j = 1, . . . , p, are the final
estimates.
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of two subjects. Next, within each domain, we use time-lag weights ωj to integrate all the lagged
differences, and we normalize the differences by dividing them by the squared root of the dimension
of features in the domain, √sj . A critical advantage of (4.4) is that we take into account the delayed
effects of features on the outcome by implementing the time-lag weights ωj . Without the time-lag
weights, then the feature measurements taken at different days have equal weights, so the model
cannot utilize the informative time patterns. Also, compared to common kernel functions such as
the linear kernel and RBF kernel, the proposed kernel distance can alleviate the bias introduced by
different time scales of features through the normalization procedure. Otherwise, features with finer
resolutions tend to dominate the computation of between-subject distances such that the outcome
may heavily rely on the corresponding domains. Therefore, considering the effects of time-lag and
time scales, the kernel distance can be regarded as a composite score which comprehensively reflects
the difference between two samples.
4.4 Applications
4.4.1 Data Preparation
The database of the AURORA study contained 3139 participants. For the ith participant, at
time point t, the outcome variable, Yit, in (4.1) was the construct score of pain. The two domains
of feature variables in this application, Xt1 and Xt2, were activity features in Table 4.2 and HRV
features in Table 4.3, respectively. We set the maximum number of days of retrieving previous
feature variables to 2 days for both activity and HRV feature variables, so we investigated the
time-lag effect in a short term.
As the pattern in Figure 4.4 suggests, HRV features were often available during the first a few
hours of each day. During the remaining hours, the HRV features had a great proportion of missing
values. Considering the pattern of missing data, we created 4 summary statistics that calculated
the hourly mean, max, min, and standard deviation of each HRV feature. We used labels such as
NNmeanmean, NNmeanmax, NNmeanmin, and NNmeanstd to denote these metrics. We used the 44
hourly HRV features instead of the 11 original HRV features in (4.3) and (4.4).
We only treated a summary statistic as non-missing if it was calculated from one of the first 6
hours in an epoch and, in any of the 6 hours, at least 10 minutes of the original HRV features were







































































































































































Figure 4.4: Missing data pattern of HRV features for 100 randomly selected participants. Mobile
devices were refreshed at 4am or 5am UTC of each day.
were missing. Therefore, the finalized dataset included 1285 construct scores of pain collected from
632 participants. Besides activity and HRV features, we used 5 demographic variables Zi to help
predict construct scores of pain. The description and distribution of demographic variables are
listed in Table 4.4.
Finally, to overcome the problem of over-fitting, we randomly divided 80% of the participants
into training data and 20% of the participants into validation data. We adopted training data
and the technique of cross-validation to derive optimal estimates, and then we used the validation
data to evaluate our method and compare it with selected machine learning models in the existing
literature.
4.4.2 Implementation of Proposed Methods
Before implementing the proposed method, we transformed the original construct scores of pain
using the ordered quantile normalization in the bestNormalize (Peterson and Cavanaugh, 2019) R
package to fulfill the normality assumption of (4.1). In addition, we normalized all the continuous
feature variables to alleviate the bias introduced by scaling. To estimate time-lag weights, ωj , and
regression parameters, βj and γ, in (4.3), we minimized the objective function using the pracma
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Table 4.4: Demographic information of participants for predicting construct scores.
Demographic Variable Statistic Value
Highest Grade mean(sd) 15.7(2.4)
median(min, max) 15.0(9.0, 21.0)
Age mean(sd) 38.6(13.9)
median(min, max) 36.0(18.0, 74.0)
Marital Status sample size(proportion) Never married: 327(51.7%)
Other: 305(48.3%)
Gender sample size(proportion) Female: 462(73.1%)
Male: 170(26.9%)
Race sample size(proportion) Black: 235(37.2%)
Other: 397(62.8%)
(Borchers, 2019) and ADMM (You and Zhu, 2018) R packages. The tuning parameters α1 and α2
were selected from {2k : k = 0,±1, . . . ,±15} using a 5-fold cross-validation. Informative feature
variables were selected if the absolute values of their coefficients exceeded 0.01. Given the selected
featuresHit, we refit (4.3) and updated parameter estimates k̂j , γ̂, β̂j , ω̂j , and λ̂j . Next, we plugged
the time-lag weights ω̂j to (4.4) and employed the SVR model with this kernel function. In the
SVR model, tuning parameters C and ε were selected from {2k : k = 0,±1, . . . ,±15} using a 5-fold
cross-validation. The model fitting was conducted on training data by kernlab (Karatzoglou et al.,
















We chose the SVR model with the minimum WMSE as the final model. Subsequently, we applied
the finalized model to the validation data and obtained predicted construct scores of pain of the
validation data. Finally, we conducted the inverse transformation on the predicted outcome scores
and calculated the WMSE for the proposed approach.
As a comparison of the proposed method, we used five alternative models. The first two models
were linear regression models with no predictor variables and with only demographic variables.
These two models served as baseline models. The third approach was the “naive” SVR model
which treated all of the activity and HRV features at different time as independent predictors. This
approach represented a typical way to handle mobile sensor data in the existing literature. The
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fourth model was the linear regression model in (4.1), but we used the informative features remained
after feature selection instead of the whole feature set. Through this model, we tested whether
the proposed approach captured the nonlinear between-domain interactions between features. The
last candidate was the same as the proposed method, however, with the RBF kernel in the second
stage. By comparing with this model, we verified the necessity of using the proposed kernel (4.4) to
integrate different domains and improve the prediction accuracy.
Table 4.5 presents the parameter estimation and feature selection results for construct scores
of pain. We selected γ and β parameters whose absolute values were greater than 0.01. After
the filtering, we reconstructed the linear model in (4.1) with the left features and estimated their
parameters again using (4.3). As shown in Table 4.5, all the demographic variables remain in the
model. On average, less educated, elder, currently married, female, and black people have greater
construct scores of pain, and this result indicates such participants have experienced more severe
pain. Among all the activity and HRV features, Amplitude, RMSSDmean, SDNNmax, NNskewmin,
SDNNstd, and ApEnstd have relatively greater effects on construct scores of pain, and the effects are
all negative. From another aspect, we could learn the time-lag effects of mobile device features on
construct scores of pain from estimates of ωjl in Table 4.5. Since all the ωjl estimates are close to
0.5, we conclude, within each set of mobile sensor features, the features monitored on the same day
as the outcome observation and those monitored one day before have roughly equal daily effects on
the construct scores of pain. In addition, λ25 = 1 indicates the summary statistics of HRV features
of the fifth hour in an epoch fully determine the daily effect.
Finally, we used the selected features to fit the second stage model and predict the construct
scores of pain on the validation data. The prediction results of the proposed method as well as the
five alternative models are listed in Table 4.6. Compared with the intercept-only regression model,
the use of demographic features reduces the WMSE of predicted construct scores of pain from 3.100
to 2.803. Meanwhile, the models employing mobile sensor features further improve the WMSE by
0.067 to 0.283. Thus, in our data, not only demographic features but also mobile sensors features
are informative to the prediction of construct scores. The WMSE for the “naive” SVR model is
2.575 and the model includes 549 feature variables. The proposed method achieves a WMSE of
2.520, but it only uses 67 feature variables.
Also, Figure 4.5 reveals a moderate linear correlation between predicted and observed construct
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Table 4.5: Estimated parameters of features left in (4.1) for predicting construct scores of pain
Domain Feature Parameter Before selection After selection
Demographics Intercept γ0 -0.1803 -0.1994
Highest Grade γ1 -0.1608 -0.1662
Age γ2 0.2172 0.2210
Marital Status γ3 0.1453 0.1470
Gender γ4 0.1510 0.1615
Race γ5 0.2577 0.2915
Activity Amplitude β1,4 -0.1358 -0.1445
Lagged days K1 2 2
1 day ago ω11 0.4648 0.4712
Today ω12 0.5352 0.5288
Daily λ11 1 1
HRV RMSSDmean β2,7 -0.0288 -0.0183
SDNNmax β2,17 -0.0106 -0.0855
NNskewmin β2,25 -0.0375 -0.0264
SDNNstd β2,39 -0.0596 -0.0509
ApEnstd β2,44 -0.0102 -0.0075
Lagged days K2 2 2
Today ω21 0.5000 0.5000
1 day ago ω22 0.5000 0.5000
1st hour λ21 0 0
2nd hour λ22 0 0
3rd hour λ23 0 0
4th hour λ24 0 0
5th hour λ25 1 1
6th hour λ26 0 0
Note: estimators in the full model with |γ| < 0.01 and |β| < 0.01 are not listed in this table.
Table 4.6: Predicted results of construct scores on validation data for four models.
Model WMSE Number of features
Proposed model 2.520 67
Linear regression model (intercept only) 3.100 0
Linear regression model (demographic features) 2.803 5
“Naive” SVR model 2.575 549
Linear regression model (selected features) 2.736 67
2-stage model with RBF kernel 2.626 67
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scores of pain (the Pearson correlation coefficient ρ = 0.4219). If we ignore the nonlinear interactions
among features and use the linear regression model (4.1) with features left in Table 4.5 to predict
construct scores of pain, the WMSE increases from 2.520 to 2.736. Also, compared to the RBF kernel,
the proposed kernel in (4.4) improves the prediction and reduce the WMSE by 0.106. Therefore, we
draw the conclusion that the proposed method has a close performance to the sophisticated SVR
model, but has much fewer feature variables. Lastly, the use of the second stage model handles the
potential issues of the linear model, and the proposed kernel has advantages over the commonly
used RBF kernel.
Figure 4.5: Scatter plots of predicted construct scores versus observed construct scores in validation
data. Red dashed lines: lines y=x. The Pearson correlation coefficient between predicted and
observed values, ρ, is 0.4219.
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4.5 Discussion
In this chapter, we proposed a framework to estimate RDoC construct scores and identify
objective biomarkers related to APNS, using mobile sensor data from the AURORA study. The
major contribution of this framework is to create a novel two-stage model, which jointly implements
different domains of features and accounts for complicated interactions between them. In the
first stage, we select the most informative features to the estimation of outcomes through a linear
regression model with LASSO and fused LASSO penalties. To adjust for the heterogeneity between
different domains of features on different time scales, we aggregate the measurements and unify them
to the same level. We also incorporate the effect of historical feature information on the current
observations of outcomes by estimating the time-lag weights. In the second stage, we employe
the SVR model to account for between-domain interactions and estimate the possible non-linear
relationship between outcomes and features. Especially, we apply a customized kernel function
as (4.4) in the SVR model. Compared to common kernel functions such as the RBF kernel, our
kernel function reduces the heterogeneities between different domains of features by normalizing
time-lag weights and time scales. Thus, our approach tackles the challenges in the high-dimensional,
correlated, and multimodal measured mobile sensor data and takes full advantage of the available
information. Compared to popular nonparametric methods which treat features observed at different
time as independent predictors, our model leads to a better prediction accuracy but only requires
12% of the feature variables. This result suggests our method is a practical assist in the prediction
of RDoC constructs and identification of objective biomarkers.
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CHAPTER 5: EXTENSIONS AND FUTURE WORK
5.1 Identify Patient Subgroups
In Chapter 2, the estimation of both regression coefficients and correlations among latent
processes only relies on one or two health markers, so our method can be easily extended to handle
a large number of health markers. In this case, one can perform the computation by parallel
computing to save computing time and cost. Inferences on the estimators can be made based on
subsampling subsets of the data. Another extensions to the proposed method is to estimate all
regression coefficients β’s simultaneously by incorporating the entire covariance matrix Ω(t) to the
estimating equations for β’s, or to allow the marker-specific and time-sensitive bandwidth selection
during the parameter estimation (especially when the smoothness of health marker trajectories are
expected to be substantially different). Lastly, instead of the nonparametric estimation, explicitly
modeling the temporal dependence within the same health marker as well as across health markers
probably will improve the estimation. Despite the increased computational burden, an advantage of
this extension is the potential to obtain a more precise assessment of the latent process given the
entire history of health markers.
5.2 Matched Learning Model for Multicategory Treatments
As discussed in Section 3.5, the matched learning model still has room to extend and handle
with more complicated observatory data. Firstly, to better interpret the obtained results, we will
consult with physicians about the clinical meanings of identified patient subgroups and ITRs. Also,
we plan to establish theoretical properties for the proposed method. For example, proving the Fisher
consistency of the estimated decision rules. Moreover, we will further validate the proposed method
by comparing with newly published methods (Lou et al., 2018; Huang et al., 2019; Zhang et al., 2020;
Qi et al., 2020). In addition, we consider to test and incorporate the proposed method using other
data resources such as the high-dimensional measurements of biomarkers collected by mobile sensors
to recommend individual treatments. Another extension is to take other aspects of T2D control
into consideration. For instance, besides lowering the level of HbA1c, we will take into account the
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balance control of adverse events such as hypoglycemia. Lastly, considering the potential switch of
treatments after time zero and the research interest in the long-term health management, we plan
to extend the proposed method to learn the optimal dynamic treatment regimes. This extension
can be realized by substituting the value function in (3.4) with a matching-based value function for
multiple stages and using a backward induction (Liu et al., 2018).
5.3 Analysis of Mobile Sensor Data
For this topic, we applied the SVR model to capture between-modality interactions as the SVR
model performs stable for high-dimensional data. However, other nonparametric models such as
random forests, gradient boosting methods, and neural networks can be similarly implemented. In
future research, we will also verify our approach on simulated datasets, additional RDoC constructs,
and different types of outcome variables such as binary or categorical outcomes. Another extension
is to take other domains of feature variables into consideration such as GPS and phone usage
data. Finally, to further improve the explainability of the model, we will explore more meaningful
summary statistics for HRV features and use the SHAP value approach (Lundberg and Lee, 2017)
to evaluate the importance of features in the final model.
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APPENDIX A: APPENDIX FOR CHAPTER 2
A.1 Gauss-Hermite Quadrature Method for Parameter Estimation
When g−1k (z) takes a general form, we can compute E [Yik(t)|Xi] and E [Yik(t)Yil(t)|Xi] using
the Gauss-Hermite quadrature method (Abramowitz and Stegun, 1965). Suppose Q is the number





































where Rkl(t) is chosen as the 2× 2 square-root matrix of Σkl(t), and [Rkl(t)]i,j denotes the entry in
the ith row and jth column of Rkl(t).
On the other hand, we can compute E
[
εi(t)







P (Yi(t)|εi(t))P (εi(t)) εi(t)dεi(t)∫































































































with R̃(t) being the square-root matrix of Ω̂(t), and
[R̃(t)]k,l is the entry in the kth row and lth column of R̃(t).
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A.2 Proof of Theorem 2.3.1
Without loss of generality, we prove the theorem 2.3.1 for one health marker k, and the results
can be generalized to other health markers. The key idea is to establish the following relationship,
for













1 + h1/21n + (nh1n)1/2
∥∥∥βk(t)− β0k(t)∥∥∥) , (A.1)
where Ak(t) is defined in (2.10).
We introduce notations Pn and P to denote the empirical and true probability measure
respectively. Then we obtain
Un,k(βk(t)) = (Pn − P )
[∫




Kh1n(s− t)X[Yk(s)− Ek(βk(t), t)]dÑk(s)
]
= I + II, (A.2)







For the second term on the right-hand side of (A.2), we have
E
[∫






X [Yk(s)− Ek(βk(t), t)] exp
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X [Yk(s)− Ek(βk(t), t)] exp
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XT (γ0k − γ̂k)
} ]
ds, (A.3)
where f(εk(s)) is the density function of a normal distribution with mean 0 and variance ck. To
simplify the expressions in the following proofs, we denote εk(s), f(εk(s)), and h1n to ε, fk,s(ε)),
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and h, respectively. Let s = t + hz and perform the Taylor expansion of (A.3) at t. Noticing∫
K(z)dz = 1 and
∫
zK(z)dz = 0, we have
E
[∫












































































After the Taylor expansion of (A.4) at γ0k , η0k, and β0k(t), we have
E
[∫












































































































(∥∥∥βk(t)− β0k(t)∥∥∥)+ op (∥∥∥γ̂k − γ0k∥∥∥)+ op (∥∥∥η̂k − η0k∥∥∥)+Op (h2) . (A.5)
From Zeng and Lin (2006), we know
n1/2
{
(γ̂k − γ0k)T , (η̂k − η0k)T
}T
→d N (0,V ). (A.6)
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Hence, n1/2






























. For any fixed t, if there exists a ζ
such that ζTAk(t)ζ = 0, then ζTX = 0, so ζ = 0 from condition 2. Thus, Ak(t) is a non-singular
matrix. Furthermore, using the similar arguments in Cao et al. (2015), we could obtain the first
term in the right-hand side of (A.2), for a M > 0 and
∥∥βk(t)− β0k(t)∥∥ < M(nh)−1/2, is equal to
















Combining (A.7) and (A.8), we obtain (A.1). From (A.1), we conclude that there exists a






























. For s, t ∈ [0, τ ],


























i=1Wi(t). Since (Xi, Yik), i = 1, . . . , n are i.i.d,










{E [Var [Wi(t)|Xi, εik(s), Nik(s)]] + Var [E [Wi(t)|X, εik(s), Nik(s)]]} . (A.11)
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Since



















































We assume, for s1 6= s2, P {dNk(s1) = 1|Nk(s2)−Nk(s2−) = 1} = pk(s1, s2)ds1, where pk(s1, s2)
is continuous for s1 6= s2, and pk(s1±, s2±) exists. To simplify the expressions in (A.12), we denote
Fk(t) = Yik(t) exp
{
−XTi γ̂k − LTik(t)η̂k
}
,

















Var [Fk(t)|X, εk(t)] = σ2 (t,X, εk(t)) ,
Cov [Fk(s), Fk(t)|X, εk(s), εk(t)] = r (s, t,X, εk(s), εk(t)) . (A.14)
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Using conditioning arguments, the expectation of (A.12) is
































































= I11 + I12 − I2. (A.15)

























































































































+Op (h) . (A.16)
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By (A.12), (A.16), and condition 3, we have












+Op (h) . (A.17)
For the second term on the right-hand side of (A.11), we have








































g−1k (XTi β0k(s) + εik(s))− g
−1
k (XTi β0k(t) + εik(t))
]
,




























































= I31 + I32 − I4. (A.19)







































































i · 0 · Λk(t)
]2 +Op (h)
































By (A.18), (A.20), and condition 3, we have
Var [E [Wi(t)|Xi, εik(s), Nik(s)]] = Op (h) . (A.21)














= Σk(t) +Op (h) . (A.22)
Thus, for each fixed time point t,
∑n
i=1 Var [Wi(t)] converges to a constant Σk(t) as h→ 0. To
prove the asymptotic normality, we verify the Lyapunov condition. Through the similar calculations






















→d N (0,Σk(t)) . (A.23)
















A.3 Proof of Theorem 2.3.2
Without loss of generality, we prove the theorem 2.3.2 for two health markers k and l, and
the results can be generalized to other health markers. The key idea is to establish the following
relationship, for












∣∣∣σkl(t)− σ0kl(t)∣∣∣) , (A.25)
where Bkl(t) is defined in (2.10).
We introduce notations Pn and P to denote the empirical and true probability measure
respectively. Then we obtain
Un,k,l(σkl(t)) = (Pn − P )
[∫∫





K̃h2n(sk − t, sl − t) [Yk(sk)Yl(sl)− Ekl(σkl(t), t)] dÑk(sk)dÑl(sl)
]
= I + II, (A.26)
where Ekl(σkl(t), t) = E[Yik(t)Yil(t)|Xi] = Eε
[
g−1k (XT β̂k(t) + εk(t))g
−1




For the second term on the right-hand side of (A.26), we have
E
[∫∫






















K̃h2n(sk − t, sl − t)E
[[
g−1k (X
Tβ0k(sk) + εk(sk))g−1l (X
Tβ0l (sl) + εl(sl))
−g−1k (X
T β̂k(t) + εk(t))g−1l (X












To simplify the expressions in the following proofs, we denote h2n to h. Using the similar
calculations as those in proving theorem 2.3.1, we apply the Taylor expansion of (A.27) at γ0k(t),






Tβ0k(t) + εk(t))g−1l (X




















∣∣∣σkl(t)− σ0kl(t)∣∣∣+Op(n1/2h3)+ op (h ∣∣∣σkl(t)− σ0kl(t)∣∣∣) . (A.28)






= (nh2)1/2(Pn − P )
[∫∫








Combining (A.28) and (A.29), we obtain (A.25). From (A.25), we conclude that there exists a






∣∣∣σkl(t)− σ0kl(t)∣∣∣+Op(n1/2h3)+ op (1 + h ∣∣∣σkl(t)− σ0kl(t)∣∣∣) . (A.30)





















Then (nh2)1/2{Un,k,l(σ0kl(t))− E[Un,k,l(σ0kl(t))]} =
∑n
i=1 Vi(t). Since (Xi, Yik), i = 1, . . . , n are














Var [E [Vi(t)|Xi, εik(sk), εik(sl), Nik(sk), Nil(sl)]] . (A.32)
For t1, t2, s1, s2 ∈ [0, τ ], we denote
Var [Fk(t1)Fl(t2)|X, εk(t1), εl(t2)] = ψ2(t1, t2,X, εk(t1), εl(t2)) (A.33)
and
Cov [Fk(t1)Fl(t2), Fk(s1)Fl(s2)|X, εk(t1), εl(t2), εk(s1), εl(s2)]
=u(t1, t2, s1, s2,X, εk(t1), εl(t2), εk(s1), εl(s2)). (A.34)
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Similarly to the calculation of Σk(t), we obtain























K̃h(tk − t, tl − t)K̃h(sk − t, sl − t)
[
u(tk, tl, sk, sl,Xi, εik(tk), εil(tl),
εik(sk), εil(sl)) + {Gk(tk)Gl(tl) + r(tk, tl,Xi, εik(tk), εil(tl))} {Gk(sk)Gl(sl)























































































K̃h(sk − t, sl − t) exp
{



































































= Σkl(t) +Op(h2). (A.37)
Thus, for each fixed time point t,
∑n
i=1 Var [Wi(t)] converges to a constant Σkl(t) as h→ 0. To
prove the asymptotic normality, we verify the Lyapunov condition. Through the similar calculations





















→d N (0,Σkl(t)). (A.38)
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A.4 Validation on Assumption of Constant Variance
Table A.1: Estimated variances using different 2-year data from EHRs at the OSU-WMCIW.
Marker Start Time End Time Estimated Variance































Table A.2: Estimated variances using 5-year data from EHRs at the OSU-WMCIW.
Marker Start Time End Time Estimated Variance
HBP 01/01/2013 12/31/2017 1.681
TC 01/01/2013 12/31/2017 0.513
HbA1c 01/01/2013 12/31/2017 0.648
HDL 01/01/2013 12/31/2017 0.721





































































































































































Figure A.1: Blue curves: new estimators for regression coefficients βk(t) across 61 time points



















































































Figure A.2: Blue curves: new estimators for correlation coefficients σkl(t) across 61 time points
using variances estimated from 2013 to 2017 EHRs data at the OSU-WMCIW. Red curves: original
estimators σ̂kl(t).
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Figure A.3: Blue curves: new estimators for regression coefficients βk(t) across 61 time points
using a suboptimal bandwidth h1n = 429.864 days. Green curves: new estimators for regression
coefficients βk(t) across 61 time points using a suboptimal bandwidth h1n = 604.132 days. Red
curves: original estimators β̂k(t) from EHRs at the OSU-WMCIW using the optimal bandwidth
















































































Figure A.4: Blue curves: new estimators for correlation coefficients σkl(t) across 61 time points
using a suboptimal bandwidth h2n = 429.864 days. Green curves: new estimators for correlation
coefficients σkl(t) across 61 time points using a suboptimal bandwidth h2n = 564.112 days. Red
curves: original estimators σ̂kl(t) from EHRs at the OSU-WMCIW using the optimal bandwidth
h2n = 494.687 days.
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Table A.3: Canberra distances between estimators of regression coefficients βk(t) using optimal and
suboptimal bandwidths.
Marker Parameter Distance Distance
(H1 = 564.112 days) (H
′
1 = 429.864 days) (H
′
1 = 604.032 days)
HBP β10 0.0022 0.0005
Binary β11 0.0094 0.0019
β12 0.0123 0.0039
β13 0.0091 0.0025
TC β20 0.0160 0.0042
Continuous β21 0.0046 0.0009
β22 0.0038 0.0009
β23 0.1722 0.0500
HbA1c β30 0.0207 0.0062
Continuous β31 0.0059 0.0016
β32 0.0923 0.0214
β33 0.0199 0.0049
HDL β40 0.0254 0.0061
Continuous β41 0.0105 0.0028
β42 0.0020 0.0006
β43 0.0115 0.0028
Number of Medications β50 0.0007 0.0002
Count β51 0.0277 0.0072
β52 0.0094 0.0029
β53 0.2615 0.2525
Table A.4: Canberra distances between estimators of correlation coefficients σkl(t) using optimal
and suboptimal bandwidths.
Parameter Distance Distance
(H2 = 494.687 days) (H
′
2 = 429.864 days) (H
′












A.6 Validation on Structure of Intensity Function
Table A.5: Effects of demographic variables and historical HbA1c levels on the frequency of health
marker measurements.
Marker Demographic Est HR SE Z P-value
HBP age 0.062 1.064 0.006 9.820 < 0.001
sex 0.060 1.062 0.014 4.290 < 0.001
race -0.132 0.876 0.015 -9.011 < 0.001
historical HbA1c -0.029 0.971 0.009 -3.110 0.002
TC age 0.015 1.015 0.006 2.251 0.024
sex -0.058 0.944 0.013 -4.336 < 0.001
race -0.020 0.981 0.015 -1.356 0.175
historical HbA1c -0.077 0.926 0.010 -7.606 < 0.001
HbA1c age 0.020 1.020 0.005 4.314 < 0.001
sex 0.026 1.026 0.010 2.704 0.007
race -0.021 0.979 0.010 -2.213 0.027
historical HbA1c 0.094 1.098 0.005 18.345 < 0.001
HDL age 0.046 1.047 0.005 9.624 < 0.001
sex -0.011 0.989 0.010 -1.068 0.285
race -0.008 0.992 0.010 -0.822 0.411
historical HbA1c -0.012 0.988 0.007 -1.807 0.071
Medications age 0.043 1.044 0.006 7.308 < 0.001
sex 0.086 1.090 0.012 7.074 < 0.001
race -0.113 0.893 0.013 -8.960 < 0.001





























































































































































Figure A.5: Blue curves: new estimators for regression coefficients βk(t) across 61 time points using
historical HbA1c levels. Red curves: original estimators β̂k(t) from EHRs at the OSU-WMCIW.





















































































Figure A.6: Blue curves: new estimators for correlation coefficients σkl(t) across 61 time points using
historical HbA1c levels. Red curves: original estimators σ̂kl(t) from EHRs at the OSU-WMCIW.
Salmon-colored ribbons: 95% confidence intervals for original estimators σ̂kl(t).
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APPENDIX B: APPENDIX FOR CHAPTER 3
B.1 Simulation Study for Multivariate Latent Modelling Method
We conducted a simulation study to examine the finite sample performance of the proposed latent
modelling approach in Chapter 3 of the main text. In this simulation study, we simulated 100 datasets
of two health markers for 10,000 subjects. We assumed Yi1(t) was Gaussian distributed and Yi2(t)
was Bernoulli distributed. Thus, g−11 (z) = z and g
−1
2 (z) = ez/(1+ez). Since the distribution of Yi1(t)
had a dispersion parameter, we set φi1(t) = 0.1. For the ith subject, we generated two covariates
Xi1 ∼ N (0, 1/3) and Xi2 ∼ Bernoulli(0.5)− 0.5. Thus, Xi = (1, Xi1, Xi2)T was a 3-dimensional
vector of baseline variables. The maximum observation time Ti for each subject was set to 12 days.
The measured time points for simulated markers were generated from two Poisson processes, and their
intensity functions were E [dNi1(t)|Xi] = exp {0.5Xi1 + 0.25Xi2 + 0.3Li11(t)− 0.1Li12(t)} dt and
E [dNi2(t)|Xi] = 1.2 exp {0.5Xi1 + 0.25Xi2 + 0.3Li21(t)− 0.1Li22(t)} dt. In the intensity functions,
we let Lik1(t) = 1 if there existed measurements of kth marker in [t− 3, t); otherwise, Lik1(t) = 0.
If Lik1(t) = 1, then Lik2(t) was the average value of all Yik(t) in [t − 3, t); otherwise, Lik2(t) = 0.




 −1.36 + t10 sin(0.76 + t) cos(−0.3 + t)
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 .
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cos(t− 0.5) sin(t+ 3)

and






)2} Ω(t) + Ω(s)
2 ,
where b = 0.5.

































We extended the data-adaptive method in Cao et al. (2015) and selected the optimal bandwidths
among 0.1, 0.2, . . . , 0.5. We found h = 0.3 for βk(t) and h = 0.2 for σkl(t) were close to the optimal
values. This set of bandwidth was used in all subsequent simulations. Since the proposed estimation
method was expected to have more stable performance at time points that not on two ends, we
estimated βk(t), σkl(t), and correlation coefficients ρkl(t) at time points t = 3, 4, . . . , 11 days.
Detailed examples on the code scripts of this simulation study can be accessed via https:
//github.com/jitonglou/EHR_ITR. Using one of the 100 simulated dataset, we provide explanatory
codes and corresponding R workspaces which follow the workflows shown in Figure B.1.
Explanatory R scripts Workflow Outputs
Generate simulated data for the workflow. TRule_simdata_GenerateData_seed72_workspace.RData
Estimate regression parameters, 𝛽𝛽𝑘𝑘 𝑡𝑡 , and the 
covariance matrix of latent processes, Ω(𝑡𝑡).


















Use �𝛾𝛾𝑘𝑘, �𝜂𝜂𝑘𝑘. 
Use �𝛾𝛾𝑘𝑘, �𝜂𝜂𝑘𝑘, ?̂?𝛽𝑘𝑘(𝑡𝑡), �Ω(𝑡𝑡). 
Use 𝑆𝑆𝑖𝑖𝑖𝑖. 
Figure B.1: Flow-chart of identifying latent subject subgroups using a simulated dataset.
Figure B.2 presents the true parameters versus estimators across the nine time points for βk(t),
k = 1, 2. From Figure B.2, we can conclude β1·(t) are close to the true parameters at each time point
of interest, and they well capture the underlying smooth function of βk(t) across time. Compared
with β̂1·(t), the biases and variations of β̂2·(t) seem greater. However, all of β2·(t) are in the
interquartile ranges of β̂2·(t), indicating reasonable estimation results.
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Figure B.2: Estimated regression coefficients β̂1(t) and β̂2(t) across 9 time points, based on 100































2.5 5.0 7.5 10.0
Days
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Figure B.3: Top panel: estimated covariance parameters σ̂12(t) across time points, based on 100
simulated datasets. Bottom panel: estimated correlation parameters ρ̂12(t) across time points, based
on 100 simulated datasets. Red: true parameters and functions. Blue: estimators.
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and ρ12(t). In both panels of Figure B.3, the mean and median of estimators are close to the true
parameters. Also, σ12(t) and ρ12(t) are in the interquartile ranges of the estimators. The results
in Figure B.3 suggest we can use σ̂12(t) and ρ̂12(t) to approximate the covariance and correlation
structure of the simulated latent processes. Therefore, the proposed estimation method performs
consistently and the biases of estimators are fairly acceptable.
B.2 Results from Latent Models in EHRs Analysis
To estimate the parameters in the joint models, we first implemented the adaptive method of
bandwidth selection as stated in Cao et al. (2015) and chose optimal bandwidths among 3, 6, and 9
months. We ended up to select h = 9 months for regression coefficients, h = 3 months for variances,
and h = 9 months for correlations as the optimal bandwidths. Using the optimal bandwidths, we
estimated βk(t), σ2k(t), and σ2kl(t) at 25 time points.
The results are presented in Figure B.4, Figure B.5, and Figure B.6, respectively. The salmon-
colored ribbons in these two figures are 95% confidence intervals for the parameters based on 100
bootstrap datasets.
Figure B.4 presents the relationships between each pair of health markers and covariates. In
general, all health markers exhibit changes over time. Mean HbA1c (β̂20(t)) has an increasing trend
after about 200 days, which may suggest the difficulty to achieve long-term control of glycemic levels
in a chronically ill patient population. Mean SBP (β̂10(t)) and BMI (β̂40(t)) show decreasing trends
over time, suggesting relatively good control of blood pressure and body mass. Mean HDL (β̂30(t))
increases during the first one year and has an decreasing trend afterwards, which may suggest
the improvement in control of cholesterol in this patient population. The estimated regression
coefficients for covariates, i.e., the estimated effects of covariates on health markers, do not show
any pattern of drastic changes over time. Instead, the estimated values across time fluctuate around
mean values. β̂11(t) and β̂31(t) are positive across time, while β̂21(t), β̂41(t), β̂51(t), and β̂61(t) are
negative. Hence, estimators β̂·1(t) suggest that elder subjects on average have higher SBP and
HDL but they have lower HbA1c, HDL, DD, and logMed. Similarly, estimators of sex effect, β̂·2(t),
suggest that compared to men, women tend to have higher expected means of HDL and BMI, but
they have lower accesses to DD and logMed. There is no apparent difference in the average values
of SBP and HbA1c between elder subjects and younger subjects. For race, the estimators of β̂·3(t)
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Figure B.4: Estimated regression coefficients β̂k(t) across 25 time points. Salmon-colored ribbons:
95% confidence intervals for the estimators based on 100 bootstrapped datasets.
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Figure B.5: Estimated variance parameters σ̂2k(t) across 25 time points. Salmon-colored ribbons:
95% confidence intervals for the estimators based on 100 bootstrapped datasets.
Figure B.5 presents the estimated variances of the latent process of each health marker. The
results suggest, in general, the variances fluctuate across time, and they do not have apparent
patterns. However, there is one fact worth mention that the variances of HbA1c and logMed have
observable increases after 1.5 years. This phenomenon may reflect the outcome of long-term control
of HbA1c varies a lot among the population, so that the number of prescribed medications are
different among patients.
Figure B.6 presents the correlations between each pair of latent processes of health markers
at three time points. The results suggest the concurrent correlations between SBP and HbA1c,
SBP and BMI, HbA1c and DD, DD and logMed are positive and moderate. Moreover, there exist
negative and observable concurrent correlations between HDL and BMI, BMI and logMed. One
interesting observation from Figure B.6 is that the estimated correlation between DD and logMed is
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Figure B.6: Estimated correlation parameters σ̂kl(t) at t = 6, 12, 18 months prior to baseline
treatment dates.
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since as a patient receives more medications then the prescription is more likely to contain diabetic
drugs. In addition, the estimated correlation between HbA1c and DD fluctuates around 0.4. This
may suggest that the patients in this cohort had a greater possibility to receive diabetic drugs if














Figure B.7: Dendrogram of Mahalanobis distances for 8,456 patients.
Finally, we computed the similarity between each pair of patients using the Mahalanobis distance
defined in (2.7). To compute ε̂i(t), we substituted Yi(t) with the nearest neighbor observation
of time t for patient i. Using the between-patient similarity matrix, we performed a hierarchical
clustering on the 8,456 patients, and the results are given in Figure B.7. We observed 5 clusters
within which patients had similar health profiles.
B.3 Coding Examples for Learning ITRs
In the github repository https://github.com/jitonglou/EHR_ITR, we also provide coding
examples for learning ITRs as Figure B.8.
Since we were not allowed to release the EHR dataset, we illustrated the proposed method
using the same simulated dataset in section B.1. After the estimation of parameters βk(t) and Ω(t),
we calculated the similarity between each pair of subjects and performed a hierarchical clustering
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Explanatory R scripts Workflow Outputs
Calculate pre-treatment covariates and 
variables reflecting recent patterns of health 
markers, 𝑍𝑍𝑖𝑖.
Create clinical outcomes 𝑅𝑅𝑖𝑖.
Estimate propensity and prognostic scores, and 
construct feature variables 𝐻𝐻𝑖𝑖.
Learn ITRs within each identified subgroup.
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Figure B.8: Flow-chart of learning optimal ITRs in a simulation study.
analysis on the similarity matrix. Some subjects had no measurement for both health markers
or had outliers. Thus, we excluded these subjects and the sample size for the dataset was 8,337
subjects. Subsequently, we clustered these subjects into three subgroups. Next, we prepared a
dataset for learning ITRs. In particular, for the ith subject, we created two variables reflecting
recent patterns of health markers by calculating the average value of Yi1(t) and Yi2(t) between t = 3
and t = 11. We denoted these two variables to Vi1 and Vi2. Then, we simulated the outcome reward
Ri = 1 +Xi1 −Xi2 + 2Vi1 − 2Vi2 + ei,
where ei ∼ N (0, 1/3). Afterwards, the ith subject was randomly assigned a treatment Ai in
{A,B,C} with equal probabilities, and the resulting dataset had 8,330 subjects of three treatments
in three subgroups. We let Zi = (Xi1, Xi2, Vi1, Vi2)T and denoted u to a certain treatment selected
from {A,B,C}. Within each subgroup, we estimated the propensity scores π(Zi) = P (Ai = u|Zi)
by a 10-fold cross-validation random forests with 3 repeats. Similarly, we estimated the prognostic
scores ψ(Zi) = E (Ri|Zi) by a gradient boosting model with 5,000 trees of which the maximum
depth was 4. Lastly, we used Hi = (Zi, π̂(Zi), ψ̂(Zi)), Ai, and Ri to estimate ITRs. After the





i I (Ai = D(Zi)) = u)Ri/π̂(Zi)∑
u
∑
i I (Ai = D(Zi)) = u) /π̂(Zi)
B.4 Empirical HbA1c Values of Estimated ITRs
Table B.1: Comparison of ITRs using M-learning and Q-learning in terms of the empirical value
function for the expected HbA1c level using 2-fold cross-validation with 100 repeats (a lower value
means more beneficial).
Group Model Mean (sd) Median (Q1,Q3)
Group 1 M-learning, SVM RBF kernel 6.362 (0.070) 6.359 (6.322, 6.400)
Q-learning, random forest 7.042(0.098) 7.034 (6.977, 7.106)
Q-learning, SVM RBF kernel 6.696 (0.073) 6.572 (6.524, 6.626)
Universal rules: MET: 6.911, INS: 7.335, Other: 7.162, Multiple: 7.375
Group 2 M-learning, SVM RBF kernel 6.397 (0.018) 6.398 (6.384, 6.407)
Q-learning, random forest 7.284(0.051) 7.286 (7.251, 7.320)
Q-learning, SVM RBF kernel 6.776 (0.031) 6.775 (6.761, 6.794)
Universal rules: MET: 6.922, INS: 7.472, Other: 7.329, Multiple: 7.473
Group 3 M-learning, SVM RBF kernel 6.597 (0.045) 6.592 (6.564, 6.629)
Q-learning, random forest 7.550(0.068) 7.554 (7.514, 7.597)
Q-learning, SVM RBF kernel 6.712 (0.057) 6.705 (6.673, 6.749)
Universal rules: MET: 7.073, INS: 7.711, Other: 7.560, Multiple: 7.792
Group 4 M-learning, SVM RBF kernel 7.752 (0.117) 7.765 (7.670, 7.810)
Q-learning, random forest 9.052(0.163) 9.071 (8.947, 9.166)
Q-learning, SVM RBF kernel 7.794 (0.131) 7.793 (7.708, 7.879)
Universal rules: MET: 8.479, INS: 9.199, Other: 8.866, Multiple: 9.121
Group 5 M-learning, SVM RBF kernel 6.464 (0.057) 6.462 (6.429, 6.502)
Q-learning, random forest 7.393(0.082) 7.389 (7.338, 7.441)
Q-learning, SVM RBF kernel 6.697 (0.041) 6.694 (6.672, 6.724)
Universal rules: MET: 6.943, INS: 7.717, Other: 7.378, Multiple: 7.443
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